



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |    |  |
|---|----|--|
| (51) International Patent Classification <sup>7</sup> :<br><br>A61K   | A2 | (11) International Publication Number: <b>WO 00/62735</b><br><br>(43) International Publication Date: 26 October 2000 (26.10.00)   |
| <p>(21) International Application Number: PCT/US00/10204</p> <p>(22) International Filing Date: 17 April 2000 (17.04.00)</p> <p>(30) Priority Data:<br/>09/292,376 15 April 1999 (15.04.99) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application<br/>US 09/292,376 (CIP)<br/>Filed on 15 April 1999 (15.04.99)</p> <p>(71) Applicant (for all designated States except US): PRO-VIRUS, INC. [US/US]; 16020 Industrial Drive, Gaithersburg, MD 20877 (US).</p> <p>(72) Inventors; and<br/>(75) Inventors/Applicants (for US only): ROBERTS, Michael, S. [US/US]; 105 Colony Court, Walkersville, MD 21793 (US). LORENCE, Robert, M. [US/US]; 9506 Nowell Drive, Bethesda, MD 20817 (US). GROENE, William, S. [US/US]; 5746 Windsong Court, New Market, MD 21774 (US). RABIN, Harvey [US/US]; 11021 Ralston Road, Rockville, MD 20852 (US). VON BORSTEL, Reid, W. [US/US]; 8310 Fox Run, Potomac, MD 20854 (US).</p> |    | <p>(74) Agent: BYRNE, Thomas, E.; Nixon &amp; Vanderhye P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b><br/><i>Without international search report and to be republished upon receipt of that report.</i></p> |
| <p>(54) Title: TREATMENT OF NEOPLASMS WITH VIRUSES</p> <p>(57) Abstract</p> <p>The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.</p>   |    |  |

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakstan                                | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

**TREATMENT OF NEOPLASMS WITH VIRUSES****Field of the Invention**

5 The subject invention relates to viruses that are able to replicate in and cause the death of neoplastic cells with a deficiency in the interferon (IFN)-mediated antiviral response. RNA and DNA viruses are useful in this regard. The invention also relates to the use of these viruses for the treatment of neoplastic diseases including cancer and large tumors.

**Background of the Invention**

10 Neoplastic disease which includes cancer is one of the leading causes of death among human beings. There are over 1.3 million new cases of cancer diagnosed in the United States each year and 550,000 deaths. Detecting cancer early, before it has spread to secondary sites  
15 in the body, greatly increases a host's chances of survival. However, early detection of cancer is not always possible, and even when it is, treatments are unsatisfactory, especially in cases of highly malignant cancers. Cancer treatments, including chemotherapy and radiation, are much less effective in later stages, especially when neoplastic growths are large and/or constitute a high tumor burden. (See Hillard Stanley, Cancer Treat. Reports, Vol. 61, No. 1, Jan/Feb 1977, p.29-36, Tannock, Cancer Research, 42, 4921-4926, Dec. 1982).  
20

Tumor regression associated with exposure to various viruses has been reported. Most of the viruses described are pathogenic in humans, and include mumps and measles. The effect of other specific viruses on particular types of cancer cells has also been described. Smith et al, (1956) Cancer, 9, 1211 (effect of adenovirus on cervix carcinoma); Holzaepfel et al,  
25 (1957) Cancer, 10, 557 (effect of adenovirus on epithelial tumor); Taylor et al, (1970) J. Natl. Cancer Inst., 44, 515 (effect of bovine enterovirus-1 on sarcoma-1); Shingu et al, (1991) J. General Virology, 72, 2031 (effect of bovine enterovirus MZ-468 on F-647, a leukemia cells); Suskind et al, (1957) PSEBM, 94, 309 (effect of coxsackie B3 virus on HeLa tumor cells); Rukavishnikova et al, (1976) Acta Virol., 20, 387 (effect of influenza A strain on  
30 ascites tumor).

The earliest references described partial tumor regression in patients treated with live attenuated viral vaccine with the aim to vaccinate them against smallpox or rabies. See DePace, N.G. (1912) Ginecologia, 9, 82-88; Salmon, P. & Baix (1922) Compt. Rend. Soc. Biol., 86, 819-820. Partial regression of tumors and regression of leukemias have also been

noted during naturally occurring measles infections. See Pasquinucci, G. (1971) Lancet, 1, 136; Gross, S. (1971) Lancet, 1, 397-398; Bluming, A.Z. and Ziegler, J.L. (1971) Lancet, 2, 105-106. In one study of 90 cancer patients intentionally infected with live mumps virus, partial tumor regression was noted in 79 cases. See Asada (1994) Cancer, 34, 1907-1928.

While the side effects of these viruses were temporary, serious sequela of infection with these human pathogens is of major concern.

\* \* \*

Viruses are categorized as follows [see Murphy A and Kingsbury DW, 1990, In: Virology, 2<sup>nd</sup> Edition (Ed. Fields, B.N.), Raven Press, New York, pp 9-35]:

| Dividing Characteristics  | Virus Family Names                                     |
|---|--|
| RNA viruses   |  |
| ss <sup>a</sup> RNA, positive-sense,<br>nonsegmented,<br>nonenveloped,            | <i>Picornaviridae, Calciviridae</i>                    |
| ssRNA, positive-sense,<br>nonsegmented,<br>enveloped,                             | <i>Togaviridae, Flaviviridae,<br/>Coronaviridae</i>    |
| ssRNA, negative-sense,<br>nonsegmented,<br>enveloped,                             | <i>Rhabdoviridae, Filoviridae,<br/>Paramyxoviridae</i> |
| ssRNA, negative-sense,<br>segmented, enveloped                                    | <i>Orthomyxoviridae</i>                                |
| ssRNA, ambisense,<br>segmented, enveloped   | <i>Bunyaviridae, Arenaviridae</i>                      |
| ds <sup>b</sup> RNA, positive-sense<br>segmented,<br>nonenveloped                 | <i>Reoviridae, Birnaviridae</i>                        |
| ssRNA, DNA step in<br>replication, positive-<br>sense, nonsegmented,<br>enveloped | <i>Retroviridae</i>                                    |



## DNA viruses

|                        |  |
|------------------------|--|
| ss/dsDNA, nonenveloped | <i>Hepadnaviridae</i>                                    |
| ssDNA, nonenveloped    | <i>Parvoviridae</i>                                      |
| 5 dsDNA, nonenveloped  | <i>Papovaviridae, Adenoviridae</i>                       |
| dsDNA, enveloped       | <i>Herpesviridae, Poxviridae,</i><br><i>Iridoviridae</i> |

<sup>a</sup> ss = single stranded<sup>b</sup> ds = double-stranded

10

Included among the family Herpesviridae (or Herpesviruses), are the subfamilies Alphaherpesvirus (including Genus Varicellavirus and Genus Simplexvirus), Betaherpesvirus, and Gammaherpesvirus.

15 Newcastle disease virus ("NDV") is a member of the Paramyxoviridae (or Paramyxoviruses). The natural hosts for NDV are chickens and other birds. NDV typically binds to certain molecules on the surface of animal host cells, fuses with the cell surface, and injects its genetic material into the host. NDV is a cytotoxic virus. Once inside the cell, the viral genes direct the host cell to make copies of the virus leading to death of the host cell, releasing the copies of NDV which infect other cells. Unlike some viruses, NDV is not

20 known to cause any serious human disease. Unlike other kinds of viruses (e.g., HTLV-1, Hepatitis B), Paramyxoviruses are not known to be carcinogenic.

Temporary regression of tumors has been reported in a small number of patients exposed to NDV, See, Csatory, L.K. (1971) Lancet, 2, 825. Csatory noted the regression of a gastrointestinal cancer in a chicken farmer during an epidemic of Newcastle disease in his

25 chickens. In a similar anecdotal report, Cassel, W.A. and Garrett, R.E. (1965) Cancer, 18, 863-868, noted regression of primary cervical cancer, which had spread to the lymph nodes, in a patient following injection of NDV into the cervical tumor. Since the mechanism of tumoricidal activity was thought to be immunologic, no work was carried out to address direct tumor cytotoxicity of the virus. Instead, efforts focused upon the immuno-modulating

30 effects of NDV. See, for example, Murray, D.R., Cassel, W.A., Torbin, A.H., Olkowski, Z.L., & Moore, M.E. (1977) Cancer, 40, 680; Cassel, W.A., Murray, D.R., & Phillips, H.S. (1983) Cancer, 52, 856; Bohle, W., Schlag, P.J., Liebrich, W., Hohenberger, P., Manasterski, M., Miller, P., and Schirmacher, V. (1990) Cancer, 66, 1517-1523.

The selection of a specific virus for tumor regression was based on serendipity or trial and error in the above citations. Only recently, have rational, mechanism-based approaches for virus use in cancer treatment been developed using DNA viruses. Examples of this type of approach are found in the development of recombinant adenoviral vectors that replicate only in tumors of specific tissue origin (Rodriguez, R. et al, 1997 Cancer Res., 57:2559-2563), or those that lack certain key regulatory proteins (Bischoff, JR, et al, 1996 Science, 274:373-376). Another recent approach has been the use of a replication-incompetent recombinant adenoviral vector to restore a critical protein function lost in some tumor cells (Zhang, WW, et al, 1994 Cancer gene therapy, 1:5-13). Finally, herpes simplex virus has also been engineered to replicate preferentially in the rapidly dividing cells that characterize tumors (Mineta, T., et al, 1994 Cancer Res., 54:3963-3966).

U.S. Application Ser. No. 08/260,536, hereby incorporated by reference in its entirety, discloses the use of NDV or other Paramyxovirus in the treatment of cancer.

#### **Viral IFN transgene expression**

One common approach to the treatment of cancer with viral therapeutics has been the use of virus vectors for the delivery of certain genes to the tumor mass.

Recombinant adenovirus, adeno-associated virus, vaccinia virus and retroviruses have all been modified to express an interferon gene alone or in combination with other cytokine genes.

In Zhang et al. ((1996) Proc. Natl. Acad. Sci., USA 93:4513-4518), a recombinant adenovirus expressing a human interferon consensus (i.e., synthetic) gene was used to treat human breast cancer (and other) xenografts in nude mice. The authors concluded "...a combination of viral oncolysis with a virus of low pathogenicity, itself *resistant* to the effects of IFN and IFN gene therapy, might be a fruitful approach to the treatment of a variety of different tumors, in particular breast cancer." In contrast to subject invention which relates to interferon-sensitive viruses, Zhang et al. (1996) teach the use of an interferon-resistant adenovirus in the treatment of tumors.

In Zhang et al. ((1996) Cancer Gene Ther., 3:31-38), adeno-associated virus (AAV) expressing consensus IFN was used to transduce human tumor cells in vitro followed by injection into nude mice. The transduced tumors either did not form tumors or grew slower than the non-transduced controls. Also, injection of one transduced human tumor cell into the tumor mass of another, non-transduced tumor resulted in a small decrease in size.

In Peplinski et al. ((1996) Ann. Surg. Oncol., 3:15-23), IFN gamma (and other cytokines, expressed either alone, or in combination) were tested in a mouse breast cancer model. Mice were immunized with tumor cells virally modified with recombinant vaccinia virus. When re-challenged with tumor cells, the mice immunized with virally modified cells had statistical improvement in the disease-free survival time.

Gastl, et al. ((1992) Cancer Res., 52:6229-6236), used IFN gamma-expressing retroviral vectors to transduce renal carcinoma cells in vitro. These cells were shown to produce higher amounts of a number of proteins important for the function of the immune system.

Restifo et al. ((1992) J. Exp. Med., 175:1423-1431), used IFN gamma-expressing retroviral vector to transduce a murine sarcoma cell line allowing the tumor cell line to more efficiently present viral antigens to CD8+ T cells.

Howard, et al. ((1994) Ann. NY Acad. Sci., 716:167-187), used IFN gamma-expressing retroviral vector to transduce murine and human melanoma tumor cells. These cells were observed to increase the expression of proteins important to immune function. These cells were also less tumorigenic in mice as compared to the non-transduced parent line, and resulted in activation of a tumor-specific CTL response in vivo.

#### **Use of Therapeutic Doses of Interferon as an Adjuvant to Viral Cancer Therapy**

Because of the known immune-enhancing properties of IFN, several studies have examined the use of IFN protein in combination with other viral cancer vaccine therapies.

In Kirchner et al. ((1995) World J. Urol., 13:171-173), 208 patients were immunized with autologous, NDV-modified, and lethally irradiated renal-cell carcinoma tumor cells, and were co-treated with low dose IL-2 or IFN alpha. The authors stated that this treatment regime results in an improvement over the natural course in patients with locally-advanced renal-cell carcinoma. The dose was approximately  $3.3 \times 10^3$  to  $2.2 \times 10^5$  PFU/kg. This was a local therapy, as opposed to a systemic approach, with the goal of inducing an anti-tumor immune response.

Tanaka et al. ((1994) J. Immunother. Emphasis Tumor Immunol., 16:283-293), co-administered IFN alpha with a recombinant vaccinia virus as a cancer vaccine therapy model in mice. This study showed a statistical improvement in survivability in mice receiving IFN as compared to those that did not. The authors attributed efficacy of IFN to the induction of CD8-positive T cells in those animals.

Arroyo et al. ((1990) Cancer Immunol. Immunother., 31:305-311) used a mouse model of colon cancer to test the effect of IFN alpha and/or IL-2 co-therapy on the efficacy of a vaccinia virus colon oncolysate (VCO) cancer treatment. They found that the triple treatment of VCO+IL-2+IFN was most efficacious in this murine model. This approach relies on immunization as the mechanism of anti-tumor activity.

IFN was used in these studies to augment the ability of the cancer cells to be recognized by the immune system.

### **Objects of the Invention**

It is an object of the invention to provide viruses for the treatment of diseases including cancer.

It is a further object of the invention to provide viruses for the treatment of neoplastic diseases including cancer.

It is a further object of the invention to provide a means by which candidate viruses are selected and/or screened for use in the therapy of neoplastic diseases.

It is a further object of the invention to provide guidance in the genetic engineering of viruses in order to enhance their therapeutic utility in the treatment of neoplastic diseases.

It is a further object of this invention to provide a means with which to screen potential target cells for viral therapy with the goal of assessing the sensitivity of the candidate target cells to viral killing.

It is a still further object of this invention to provide guidance in the management of viral therapy.

It is an object of the invention to provide a method for treating large tumors.

It is a further object of the invention to provide purified virus and methods for obtaining same.

### **Summary of the Invention**

This invention relates to a method of infecting a neoplasm in a mammal with a virus comprising administering an interferon-sensitive, replication-competent clonal virus, selected from the group consisting of RNA viruses and the DNA virus families of Adenovirus, Parvovirus, Papovavirus, Iridovirus, and Herpesvirus, to the mammal.

This invention also relates to a method of infecting a neoplasm in a mammal with a virus comprising systemically administering an interferon-sensitive, replication-competent clonal virus to the mammal.

This invention also relates to a method of treating a neoplasm including cancer in a mammal comprising administering to the mammal a therapeutically effective amount of an  
5 interferon-sensitive, replication-competent, clonal virus selected from the group consisting of RNA viruses, and the DNA virus families of Adenovirus, Parvovirus, Papovavirus, Iridovirus, and Herpesvirus.

This invention also relates to a method of infecting a neoplasm in a mammal with a virus  
10 comprising administering an interferon-sensitive, replication-competent clonal vaccinia virus, having one or more mutations in one or more viral genes involved with blocking interferon's antiviral activity selected from the group of genes consisting of K3L, E3L and B18R, to the mammal.

The invention also relates to a method of treating a neoplasm including cancer in a  
15 mammal administering to the mammal a therapeutically effective amount of an interferon-sensitive, replication-competent vaccinia virus having one or more mutations in one or more viral genes involved with blocking interferon's antiviral activity selected from the group of genes consisting of K3L, E3L and B18R.

The invention also relates to a method of infecting a neoplasm at least 1 cm in size with a  
20 virus in a mammal comprising administering a clonal virus, selected from the group consisting of (1) RNA viruses; (2) Hepadenavirus; (3) Parvovirus; (4) Papovavirus; (5) Herpesvirus; (6) Poxvirus; and (7) Iridovirus, to the mammal.

The invention also relates to a method of treating a neoplasm in a mammal, comprising  
25 administering to the mammal a therapeutically effective amount of a clonal virus, selected from the group consisting of (1) RNA viruses; (2) Hepadenavirus; (3) Parvovirus; (4) Papovavirus; (5) Herpesvirus; (6) Poxvirus; and (7) Iridovirus, wherein the neoplasm is at least 1 centimeter in size.

The invention also relates to a method of treating a tumor in a mammal, comprising  
30 administering to the mammal a therapeutically effective amount of an RNA virus cytotoxic to the tumor, wherein the mammal has a tumor burden comprising at least 1.5% of the total body weight.

The invention also relates to a method of screening tumor cells or tissue freshly removed from the patient to determine the sensitivity of the cells or tissue to killing by a virus

comprising subjecting the cells or tissue to a differential cytotoxicity assay using an interferon-sensitive virus.

5 The invention also relates to a method for identifying a virus with antineoplastic activity in a mammal comprising a) using the test virus to infect i) cells deficient in IFN-mediated antiviral activity, and ii) cells competent in IFN-mediated antiviral activity, and b) determining whether the test virus kills the cells deficient in IFN-mediated antiviral activity preferentially to the cells competent in interferon-mediated antiviral activity.

10 The invention also relates to a method of making viruses for use in antineoplastic therapy comprising: a) modifying an existing virus by diminishing or ablating a viral mechanism for the inactivation of the antiviral effects of IFN, and optionally b) creating an attenuating mutation that results in lower virulence than said existing virus.

15 The invention also relates to a method of controlling viral replication in a mammal treated with a virus selected from the group consisting of RNA viruses, Adenoviruses, Poxviruses, Iridoviruses, Parvoviruses, Hepadnaviruses, Varicellaviruses, Betaherpesviruses, and Gammaherpesviruses comprising administering an antiviral compound.

The invention also relates to a method of screening tumor cells, tumor tissue, or tissue sections to determine which tumor cells or tissue allow a virus to bind comprising subjecting the cells, tissues, or tissue sections to an immunoassay or immunostain for the amount of virus receptor present on the tumor cells or tumor tissue.

20 The invention also relates to a method of infecting a neoplasm in a mammal with a virus comprising systemically administering a desensitizing dose of an interferon-sensitive, replication-competent clonal virus to the mammal before administering at least one subsequent higher dose of a virus.

25 The invention also relates to a method of infecting a neoplasm in a mammal with a virus comprising administering an interferon-sensitive, replication-competent clonal virus to the mammal over a course of at least 4 minutes.

30 This invention also relates to a method of infecting a neoplasm in a mammal with a virus comprising administering a replication-competent clonal virus selected from the group consisting of the Newcastle disease virus strain MK107, Newcastle disease virus strain NJ Roakin, Sindbis virus, and Vesicular stomatitis virus.

Included in the invention are:

- i) a clonal Paramyxovirus purified by ultracentrifugation without pelleting;
- ii) a clonal Paramyxovirus purified to a level of at least  $2 \times 10^9$  PFU per mg of protein;

iii) a clonal Paramyxovirus purified to a level of at least  $1 \times 10^{10}$  PFU per mg of protein;

iv) a clonal Paramyxovirus purified to a level of at least  $6 \times 10^{10}$  PFU per mg of protein;

5 v) a clonal RNA virus purified to a level of at least  $2 \times 10^9$  PFU per mg of protein;

vi) a clonal RNA virus purified to a level of at least  $1 \times 10^{10}$  PFU per mg of protein;

vii) a clonal RNA virus purified to a level of at least  $6 \times 10^{10}$  PFU per mg of protein;

viii) a clonal cytotoxic DNA virus which is interferon-sensitive and purified to a level of at least  $2 \times 10^9$  PFU/mg protein;

10 ix) a replication-competent vaccinia virus having a) one or more mutations in one or more of the K3L, E3L and B18R genes, and b) an attenuating mutation in one or more of the genes encoding thymidine kinase, ribonucleotide reductase, vaccinia growth factor, thymidylate kinase, DNA ligase, dUTPase;

15 x) a replication-competent vaccinia virus having one or more mutations in two or more genes selected from the group consisting of K3L, E3L, and B18R;

xi) a Herpesvirus having a modification in the expression of the (2'-5')A analog causing the Herpesvirus to have increased interferon sensitivity; and

xii) a Reovirus having an attenuating mutation at omega 3 causing said virus to become interferon-sensitive.

20 xiii) a replication competent cytotoxic virus which is interferon sensitive and purified to a level of at least  $2 \times 10^9$  PFU/mg protein.

xiv) a reovirus purified to a level of at least  $2 \times 10^9$  PFU/mg protein.

Also included in the invention are the following methods:

25 i) a method of purifying an RNA virus comprising the steps of a) generating a clonal virus; and b) purifying said clonal virus by ultracentrifugation without pelleting; or c) purifying said clonal virus by tangential flow filtration with or without subsequent gel permeation chromatography, and

30 ii) a method of purifying a Paramyxovirus comprising purifying the virus by ultracentrifugation without pelleting, or by tangential flow filtration with or without subsequent gel permeation chromatography.

The invention also relates to a method of treating a disease in a mammal, in which the diseased cells have defects in an interferon-mediated antiviral response, comprising

administering to the mammal a therapeutically effective amount of an interferon-sensitive, replication-competent, clonal virus.

The invention also relates to a method of infecting a neoplasm in a mammal with a virus comprising administering an interferon-responsive, replication-competent clonal RNA virus to the mammal.

The invention a method of treating a disease of viral etiology in a mammal comprising administering to the mammal a therapeutically effective amount of a replication-competent clonal virus.

The invention also relates to a method of infecting a neoplasm in a mammal comprising administering a virus selected from the group of families consisting of Paramyxoviridae, Orthomyxoviridae, Rhabdoviridae, Togaviridae, Flaviviridae, Picornaviridae, Coronaviridae, Reoviridae, Poxviridae, Herpesviridae, and Parvoviridae.

The invention also relates to a method of treating tumor ascites comprising administering an interferon-sensitive, replication-competent clonal virus.

The invention also relates to a method of reducing pain in a mammal comprising administering an interferon-sensitive, replication competent clonal virus.

The invention also relates to a method of treating a neoplasm in a mammal comprising subjecting a sample from said mammal to an immunoassay to detect the amount of virus receptor present, and if the receptor is present, administering an interferon-sensitive, replication competent clonal virus, which bind the receptor, to the mammal.

### **Brief Description of the Drawings**

Figure 1 shows the effect of anti-interferon-beta antibody on viral antigen expression and infectious titer in NHEK (normal human epithelial keratinocytes) cells.

Figure 2 shows the effect of interferon-beta on viral antigen expression in different cells (normal human skin fibroblasts CCD922-sk and two types of head and neck carcinoma cells (KB and Hep2 cells).

Figure 3A shows the effect of interferon on viral antigen expression in CCD922-sk cells, and Figure 3B shows the effect of interferon on viral antigen expression in KB cells.

Figure 4 shows the survival curves for athymic mice bearing human ovarian ES-2 tumors and treated with either saline or NDV.

Figure 5 shows the interferon responsiveness of a number of human tumor and normal cell lines.



Figure 6 shows the dose response of the SW620 tumor cell line to infection with PPMK107 and PPSINDBIS-Ar339.

\* \* \*

### **Detailed Description of the Invention**

5       The present invention relates to the discovery of a novel mechanism by which viral replication selectively kills neoplastic cells deficient in an interferon (IFN)-mediated anti-viral response. This invention also provides methods for selection, design, purification, and use of viruses for the treatment of neoplastic diseases including cancer and large tumors. The viruses of the invention selectively replicate in and kill neoplastic cells based on the selective  
10       deficiency in these cells of an IFN-mediated anti-viral response. Administration of the appropriate dosage of virus results in neoplastic cell death, whereas normal cells, which possess an intact IFN-mediated anti-viral response, limit the replication of the virus and are not killed. Included in the subject of the invention is the use of paramyxoviruses such as NDV, and other viruses, for use in the treatment of diseases including neoplastic disease such  
15       as cancer. The invention also teaches screening and engineering of other viruses suitable for use as therapeutics of neoplastic diseases. Another embodiment of the invention involves a method of identifying tumor tissues that are candidates for viral therapy. Finally, the invention also describes the preparation of highly purified virus.

#### **Rationale for the use of interferon-sensitive viruses including NDV to treat neoplastic disease**

##### **NDV demonstrates selective killing of tumor cells.**

Newcastle disease virus causes selective cytotoxic effects against many human tumor cells with markedly less effects on most normal human cells. In a differential cytotoxicity  
25       assay, human cancer cells derived from renal carcinomas, pancreatic carcinoma, sarcomas, melanomas, breast carcinomas, ovarian carcinomas, bladder carcinomas, colon carcinoma, prostate carcinoma, small cell and non-small cell lung carcinomas, and glioblastomas were discovered to be approximately 3 to 4 orders of magnitude more sensitive to NDV than many normal human cells [renal epithelial cells, fibroblasts, keratinocytes, melanocytes, and  
30       endothelial cells (see Example 1)]. The differential cytotoxicity assay can also be applied to fresh isolates from the patient's cells or tumor tissue.

An in vitro assay is used to define the tumoricidal activity of NDV as described in Example 1. The assay measures the amount of virus required to kill 50% of the tested cell

culture in a five day time period. Examples 2 and 3 show the results of in vivo experiments in which virus was administered to athymic mice bearing human tumor xenografts by either the intratumoral (Example 2) or intravenous (Example 3) route. These results demonstrate that NDV can cause regression of a variety of human tumor types in a standard animal model for the testing of potential chemotherapeutic agents.

Evidence that NDV is specifically replicating within the tumor was demonstrated by immunohistochemical staining for virus antigen (Example 2). Within 30 minutes of intratumoral virus injection, the tumor tissue was negative for viral antigen. However, by day 2 post treatment, intense immunostaining for viral antigen was seen within the tumor, indicating virus replication within the tumor. Importantly, virus replication was specific for the tumor tissue since the neighboring connective tissue and skin were negative for viral antigen.

Importantly, efficient replication of NDV is crucial for the ability of the virus to kill infected cells, as demonstrated in studies using UV-inactivated non-clonal virus (Lorence, R., et al, 1994, J. Natl. Cancer Inst., 86:1228-1233).

NDV can also cause regression of large tumors after intratumoral and intravenous administration (Examples 4 through 9). Intratumoral NDV treatment of large intradermal A375 human melanoma xenografts ( $\geq 10$  mm in maximal dimension; tumor volume of  $\geq 300$  mm<sup>3</sup>) in athymic mice lead to high rates of tumor regression (Examples 4 through 8). Intravenous NDV treatment of large subcutaneous HT1080 human fibrosarcoma xenografts ( $\geq 10$  mm in maximal dimension) in athymic mice lead to complete or partial tumor regression in five out of six mice (Example 9).

#### **The class I interferon family of cytokines are important negative modulators of viral infection.**

The class I interferons consist of the IFN $\alpha$ , found primarily in cells of hematopoietic origin, and IFN $\beta$  found primarily in fibroblasts and epithelial cells. [Joklik, W.K. 1990. Interferons. pp 383-410. Virology, second edition, edited by B.N. Fields, D.M. Knipe et al, Raven Press Ltd., New York; and Sreevalsan, T. 1995. Biological Therapy with Interferon- $\alpha$  and  $\beta$ : Preclinical Studies. pp 347-364. Biologic Therapy of Cancer, second edition, edited by V.T. DeVita, Jr., S. Hellman, and S.A. Rosenberg, J.B. Lippincott Company, Philadelphia.] Both types of IFN function through an apparently common mechanism of action that includes the degradation of double-stranded RNA intermediates of viral

replication, and the inhibition of cellular translation through the activity of a protein kinase activated by double-stranded RNA (Joklik, W.K. 1990. Interferons. pp 383-410. Virology. Second Edition, edited by B.N. Fields, D.M. Knipe et al., Raven Press Ltd., New York; and references therein). Several viruses (influenza, EBV, SV40, adenovirus, vaccinia) have evolved mechanisms by which one or more pathways of the IFN system are inactivated, thus allowing the efficient replication of the virus (Katze, M.G. 1995. Trends in Microbiol. 3:75-78).

**A wide variety of tumor cells are deficient in the ability to limit viral infection through an IFN-dependent mechanism.**

Human cervical carcinoma cells (HeLa) were over three-hundred-fold less sensitive to the inhibition of vesicular stomatitis virus replication following pre-treatment with IFN than a non-transformed fibroblast control cell line (Maheshwari R.K., 1983. Biochem, Biophys. Res. Comm. 17:161-168). The subject inventors have discovered that infection of a co-culture of tumorigenic human head and neck carcinoma cells (KB) and normal human skin fibroblast cells (CCD922-sk) results in viral replication initially in both cell types, followed by a limiting of the infection in the normal cells versus continued replication and killing of the tumor cells (Example 10). Moreover, although IFN was being secreted by the normal cells into the culture medium, the tumor cells were unable to respond to the IFN at the concentrations being produced to establish an antiviral state. Further evidence for the role of IFN in the differential sensitivity of tumor cells versus normal cells to killing by NDV was obtained in two separate experiments in which normal fibroblast cells (CCD922-sk) or normal epithelial keratinocyte cells (NHEK) were shown to become more sensitive to infection with NDV in the presence of neutralizing antibody to IFN (Examples 11 and 12). Finally, parallel infection of normal fibroblasts (CCD922-sk) and human tumor cells (KB) in the presence of IFN revealed that the normal cells were at least 100-fold more sensitive to the antiviral effects of added IFN than were the tumor cells (Examples 13 and 14). Similar testing of variety tumor cell lines (total of 9) revealed a clear correlation in the relative sensitivity of a cell line to killing by NDV and an inability of the cell line to manifest an interferon-mediated antiviral response (Example 26).

**Interferon and Cell Growth**

There are several species of interferon (IFN) including natural and recombinant forms of  $\alpha$ -IFN,  $\beta$ -IFN,  $\omega$ -IFN, and  $\gamma$ -IFN as well as synthetic consensus forms (e.g., as described in Zhang et al. (1996) *Cancer Gene Therapy*, 3:31-38). In addition to the anti-viral activities that lead to its discovery, IFN is now known to play an important role in the normal regulation of cell growth and differentiation. IFN is viewed as a negative growth regulator and several key proteins involved in the function and regulation of IFN activity have been shown to act as tumor-suppressor proteins in normal cells (Tanaka et al, 1994 *Cell* 77:829-839). Moreover, several other proteins known to antagonize the anti-viral activity of IFN have been shown to have oncogenic potential when expressed inappropriately (see below, Barber, GN, 1994, *Proc. Natl. Acad. Sci. USA* 91:4278-4282). Cells derived from a number of human cancers have been shown to be deleted in the genes encoding IFN (James, CD, et al, 1991, *Cancer Res.*, 51:1684-1688), and partial or complete loss of IFN function has been observed in human cervical carcinoma (Petricoin, E, et al, 1994 *Mol. Cell. Bio.*, 14:1477-1486), chronic lymphocytic leukemia (Xu, B., et al, 1994, *Blood*, 84:1942-1949), and malignant melanoma cells, (Linge, C., et al, 1995, *Cancer Res.*, 55:4099-4104).

The IFN-inducible protein kinase (p68, PKR) has been shown to be an important regulator of cellular and viral protein synthesis. A correlation has emerged that links the expression or activity of the p68 kinase to the cellular state of differentiation. Thus, poorly differentiated cells, such as those occurring in many cancers, are deficient in p68 function (Haines, G.K., et al, 1993 *Virchows Arch B Cell Pathol.* 63:289-95). Cells that lack p68 activity are generally sensitive to viral mediated killing because the p68 kinase is an important effector of the IFN-inducible antiviral state. The antiviral activity of p68 can be antagonized through a direct interaction with a cellular protein identified as p58. When cloned and overexpressed in NIH3T3 cells, p58 causes the cells to exhibit a transformed phenotype and anchorage-independent growth (Barber GN et al., 1994 *Proc Natl Acad Sci USA* 91:4278-4282), and a number of human leukemia cell lines have been shown to overexpress the p58 protein (Korth MJ, et al., 1996 *Gene* 170:181-188). The activity of p68 kinase can also be antagonized by the Ras protein. Cells that express mutant, activated forms of Ras have been shown to be defective in the activation of p68 kinase by double-stranded RNA (Mundshau, L.J., and Faller, D.V., 1992, *J. Biol. Chem.*, 267:23092-23098). Sensitivity to viral killing in undifferentiated cells can be reversed through the induction of a

more differentiated phenotype (Kalvakolanu, DVR and Sen, G.C. 1993 Proc Natl Acad Sci USA 90:3167-3171).

\* \* \*

### Definitions

5 Cells competent in an interferon-mediated antiviral response. As used herein, the term "cells competent in an interferon-mediated antiviral response" are cells which respond to low levels (e.g., 10 units per ml) of exogenous interferon by significantly reducing (at least 10-fold, more advantageously at least 100-fold, more advantageously at least 1000-fold, and most advantageously at least 10,000-fold) the replication of an interferon-sensitive virus as compared to in the absence of interferon. The degree of virus replication is determined by measuring the amount of virus (e.g., infectious virus, viral antigen, viral nucleic acid).  
10 CCD922 normal fibroblasts are cells competent in an interferon-mediated antiviral response.

15 Cells deficient in an interferon-mediated antiviral response. As used herein, the term "cells deficient in an interferon-mediated antiviral response" are cells which fail to meet the criteria listed above for a cell competent in an interferon-mediated antiviral response, that is, they fail to respond to low levels (e.g., 10 units per ml) of exogenous interferon by significantly reducing the replication of an interferon-sensitive virus as compared to in the absence of interferon. KB oral carcinoma cells are cells deficient in an interferon-mediated  
20 antiviral response.

Clonal. Use of the term "clonal" virus is defined hereafter as virus derived from a single infectious virus particle and for which individual molecular clones have significant nucleic acid sequence homology. For example, the sequence homology is such that at least eight  
25 individual molecular clones from the population of virions have sequence homology greater than 95%, more advantageously greater than 97%, more advantageously greater than 99%, and most advantageously 100% over 300 contiguous nucleotides.

30 Cytocidal. As used herein, the term "cytotoxic" virus refers to a virus that infects cells resulting in their death.

Desensitization. As used herein, the phrase desensitization refers to pretreatment with an agent that lessens the side effects caused by virus administration.

**Desensitizing Dose.** As used herein, the phrase "desensitizing dose" refers to the amount of virus required to lessen the side effects of subsequent doses of virus.

5 **Differential Cytotoxicity Assay.** As used herein, the phrase "differential cytotoxicity assay" for screening tumor cells or tissue using a virus refers to the (a) virus infection of the tumor cells and one or more control cells or tissue; (b) a determination of cell survivability or death for each sample (for example, by the use of a dye indicator of cell viability as in detailed in Example 1) after one or more days of infection; and (c) based on the results, an  
10 estimation of the sensitivity (for example, by IC50 determination as detailed in Example 1) of the sample to the virus compared to the control(s).

**Infecting a Neoplasm.** As used herein, the term "infecting a neoplasm" refers to the entry of viral nucleic acid into the neoplastic cells or tissues.

15

**Interferon-sensitive.** As used herein, the phrase "interferon-sensitive" virus (e.g., NDV) means a virus that replicates significantly less (at least 10-fold less, advantageously at least 100-fold less, more advantageously at least 1000-fold less, and most advantageously at least 10,000-fold less), in the presence of interferon compared to in the absence of interferon. This  
20 is determined by measuring the amount of virus (e.g., infectious virus, viral antigen, viral nucleic acid) obtained from cells competent in an interferon-mediated antiviral response in the presence or absence of low levels of exogenous interferon (e.g., 10 units per ml).

**Interferon-responsive.** As used herein, the phrase "interferon-responsive" virus (e.g., NDV) refers to a virus that following an infection at an moi (multiplicity of infection) of 1.0 at least  
25 50% less viral antigen is expressed in cells pretreated for 24 hours, and maintained with 500 Units/ml of the exogenous interferon- $\alpha$ , than in untreated cells. The measurements are made in cells competent in an interferon-mediated antiviral response at least 24 hours post-infection, and on the first day that would allow a determination of a 50% decrease in viral  
30 antigen expression.

**Neoplasm and Neoplastic Disease.** As used herein, "neoplasm" means new growth of tissue, including tumors, benign growths (e.g., condylomas, papillomas) and malignant

growths (e.g., cancer). As used herein, "neoplastic disease" refers to disease manifested by the presence of a neoplasm.

**Replication Competent.** As used herein, the term "replication-competent" virus refers to a virus that produces infectious progeny in neoplastic cells.

**Substantially Free of Contaminating Egg Proteins.** The term "substantially free of contaminating egg proteins" refers to a level of virus purity in which ovalbumin is not detectable in a Western blot as performed by one skilled in the art by (1) using  $1.7 \times 10^9$  PFU of virus per well (3.3 cm in width) run on an SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) gel (1 mm thick); (2) transferring the viral proteins from the gel to a nitrocellulose membrane; and (3) immunostaining for ovalbumin with the use of a rabbit anti-ovalbumin [Rabbit IgG fraction at a 1:200 dilution of a 4 mg/ml antibody concentration (from Cappel, Inc.) or equivalent polyclonal antibody] and, more advantageously, not detectable in an electrochemiluminescence assay with a sensitivity of 2.4 ng/ml.

**Therapeutically effective amount.** As used herein, the term "therapeutically effective amount" when referring to the treatment of neoplastic disease refers to a quantity of virus which produces the desired effect, e.g., cessation of neoplastic growth, tumor regression, improved clinical conditions, or increased survival.

\* \* \*

### **Compounds of the Invention**

A diverse group of viruses are used to selectively kill neoplastic cells. Natural or engineered viruses can function as an antineoplastic agent. These viruses i) infect neoplastic cells resulting in their death; ii) are replication-competent in the neoplastic cells; and iii) are limited in killing of normal cells by the antiviral effects of interferon.

In an advantageous embodiment of the invention, the viruses possessing the above three characteristics [(i) they infect neoplastic cells resulting in their death; (ii) they are replication-competent in the neoplastic cells; and (iii) they are limited in killing of normal cells by the antiviral effects of interferon] also induce interferon.

In another advantageous embodiment of the invention, the viruses possessing the above three characteristics also cause regression of human neoplasms; and/or are not neutralized in the target human population because of the presence of pre-existing immunity.

5 In another advantageous embodiment, the viruses possessing the above three characteristics are cytotoxic to tumor cells.

A Paramyxovirus (as used herein "Paramyxovirus" refers to a member of the Paramyxoviridae) can be used according to the present invention to treat a neoplasm including a large tumor or a host having a high tumor burden. The Paramyxoviridae family comprises three genera: (1) paramyxoviruses; (2) measles-like viruses (morbilli viruses); and  
10 (3) respiratory syncytial viruses (pneumoviruses). These viruses contain an RNA genome. Use of Paramyxoviridae viruses which are cytotoxic, especially paramyxoviruses, e.g., Newcastle disease virus ("NDV") and other avian paramyxoviruses such as avian paramyxovirus type 2, is an advantageous method of practicing the invention. Attenuated strains of these viruses are especially useful for treatment of neoplasms in accordance with  
15 the present invention.

NDV is an especially advantageous virus according to the present invention. NDV is categorized into three distinct classes according to its effects on chickens and chicken embryos. "Low virulence" strains are referred to as lentogenic and take 90 to 150 hours to kill chicken embryos at the minimum lethal dose (MLD); "moderate virulence" strains are  
20 referred to as mesogenic and take 60 to 90 hours to kill chicken embryos at the MLD; "high virulence" strains are referred to as velogenic and take 40 to 60 hours to kill chicken embryos at the MLD. See, e.g., Hanson and Brandly, 1955 (Science, 122:156-157), and Dardiri et al., 1961 (Am. J. Vet. Res., 918-920). All three classes are useful, advantageously, mesogenic strains of NDV such as strain MK107, strain NJ Roakin, and strain Connecticut-70726. (see  
25 Examples 21-23). See, e.g., Schloer and Hanson, 1968 (J. Virol., 2:40-47) for a listing of other mesogenic strains.

For certain purposes, it is desirable to obtain a clonal virus to ensure or increase the genetic homogeneity of a particular virus strain and to remove defective interfering particles. Removal of defective interfering particles by cloning allows for increased purity in the final  
30 product as assessed by the number of total virus particles per infectious particle (e.g., the number of particles per PFU).

Clonal virus can be produced according to any method available to the skilled worker. For example, plaque purification is routinely utilized to obtain clonal virus. See, e.g.,



Maassab et al., In: Plotkin and Mortimer, eds. Vaccines. Philadelphia: W.B. Saunders Co., 1994, pages 781-801. Triple plaque purification is especially desirable, where a plaque is selected at each round of purification having the desired characteristics, such as a preferred size, shape, appearance, or representative of the parental strain. Another means of generating clonal virus is by recombinant DNA techniques applicable by one skilled in the art. Another means of obtaining a clonal virus applies the technique of limiting dilution (e.g., by adding dilutions of the virus sample to give an average of one or less infectious virus particles per well containing a monolayer of a susceptible cell).

In an advantageous embodiment of the invention, purified virus is used to treat neoplastic diseases. An advantageous method for purification of egg derived viruses are as follows (virus is not pelleted at any step in these methods):

#### Purification Method A

- a) generating a clonal virus (e.g., plaque purification)
- b) inoculating eggs with the clonal virus
- c) incubating the eggs
- d) chilling the eggs
- e) harvesting the allantoic fluid from the eggs
- f) removing cell debris from the allantoic fluid
- h) ultracentrifugation of the allantoic fluid without pelleting (e.g., using a discontinuous sucrose gradient)

In another embodiment of the invention, additional steps, added after the removal of the cell debris (from the allantoic fluid) and before ultracentrifugation, consist of:

- freezing then thawing the allantoic fluid
- removing contaminating material from the virus suspension (e.g., by means of centrifugation)

In another embodiment of the invention, ultracentrifugation is accomplished by means of a continuous flow ultracentrifuge.

One embodiment of the invention relates to a method of purifying a replication-competent RNA virus comprising the steps of:

- a) generating a clonal virus, and b) purifying said clonal virus by ultracentrifugation without pelleting.

Another embodiment of the invention involves a method of purifying a paramyxovirus (e.g., NDV) comprising purifying the virus by ultracentrifugation

without pelleting. Optionally, the purifying step additionally comprises prior to the ultracentrifugation:

- a) plaque purifying to generate a clonal virus,
- b) inoculating eggs with the clonal virus,
- 5 c) incubating the eggs,
- d) chilling the eggs,
- e) harvesting allantoic fluid from the eggs and,
- f) removing cell debris from the allantoic fluid.

Another embodiment of the invention involves a method of purifying a replication-competent clonal virus from eggs or cell culture comprising the step of ultracentrifugation without a step in which the virus is pelleted (see Example 31).

Another embodiment of the invention involves a method of purifying a paramyxovirus (e.g., NDV) comprising purifying the virus by sequential tangential flow filtration (TFF). Optionally, the virus can be additionally purified by gel permeation chromatography, where each of these steps occurs in the presence of a stabilizing buffer (Example 15):

- a) plaque purifying to generate a clonal virus,
- b) inoculating eggs with the clonal virus,
- c) incubating the eggs,
- 20 d) chilling the eggs,
- e) harvesting allantoic fluid from the eggs and
- dilution of allantoic fluid with buffer,
- f) removing cell debris from the allantoic fluid by TFF
- g) purification of the virus by TFF
- 25 h) purification of the virus by gel permeation chromatography

Optionally, the virus obtained from the gel permeation step can be concentrated using TFF.

Another embodiment of the invention involves a method of purifying a replication-competent clonal virus from eggs or cell culture comprising the step purifying the virus by sequential tangential flow filtration (TFF), and optionally followed by gel permeation chromatography, which can optionally be followed by TFF to concentrate the virus.

Clonal virus

Use of these methods permits purification of a clonal virus [including Paramyxovirus (e.g., NDV)] to at least  $2 \times 10^9$  PFU/mg protein, advantageously to at least  $3 \times 10^9$  PFU/mg protein, more advantageously to at least  $5 \times 10^9$  PFU/mg protein, more advantageously to at least  $1.0 \times 10^{10}$  PFU/mg protein, more advantageously to at least  $2.0 \times 10^{10}$  PFU/mg protein, more advantageously to at least  $3 \times 10^{10}$  PFU/mg protein, more advantageously to at least  $4 \times 10^{10}$  PFU/mg protein, more advantageously to at least  $5 \times 10^{10}$  PFU/mg protein, and most advantageously at least  $6 \times 10^{10}$  PFU/mg.

Use of these methods permits purification of a clonal virus [including Paramyxovirus (e.g., NDV)] to level in which the number of virus particles per PFU is less than 10, more advantageously less than 5, more advantageously less than 3, more advantageously less than 2, and most advantageously less than 1.2. (Lower numbers of virus particles per PFU indicate a higher degree of purity.)

RNA viruses

In another embodiment, these methods permit purification (to the levels cited above for clonal viruses) of an RNA virus [including (a) a cytocidal RNA virus; (b) a single-stranded RNA non-segmented, nonenveloped virus; (c) a single-stranded RNA segmented, enveloped virus; (d) a double-stranded RNA segmented, nonenveloped virus; (e) and a single-stranded RNA non-segmented, enveloped virus (e.g., Paramyxovirus (c.g., NDV) and e.g., Retroviruses)].

DNA viruses

In another embodiment, these methods permit purification (to the levels cited above for clonal viruses) of an interferon-sensitive cytocidal virus selected from the group consisting of (a) enveloped, double-stranded DNA viruses (including poxviruses); (b) nonenveloped, single-stranded DNA viruses; and (c) nonenveloped, double-stranded DNA viruses.

Egg derived viruses

In another embodiment, these methods permit purification of egg derived viruses to a level substantially free of contaminating egg proteins. It is preferred to limit the amount

of egg proteins in virus preparations for human therapeutic use since major egg proteins like ovalbumin are allergens.

\* \* \*

Viruses useful in the treatment of neoplastic diseases including cancer are shown in Table 1. Additional examples of virus family members can be found in "Murphy A and Kingsbury DW, 1990, In: Virology, 2<sup>nd</sup> Edition (Ed. Fields, B.N.), Raven Press, New York" hereby incorporated in its entirety. These viruses are optionally screened for naturally occurring variations (certain strains or isolates) that result in altered IFN production relative to the parental strain.

In another embodiment of this invention, candidate viruses, whether naturally occurring or engineered, are tested for the ability to provide therapeutic utility in the treatment of neoplasms. In one embodiment, the amount of candidate virus required to kill 50% of cells deficient in an interferon-mediated antiviral response, e.g., KB head and neck carcinoma cells, is compared to the amount of virus required to kill 50% of a similar number of cells competent in an interferon-mediated antiviral response, for example normal skin fibroblasts. The amount of killing is quantified by any number of means including trypan blue exclusion or MTT assay (see Example 1). A significant reduction (e.g., at least 5-fold) in the amount of virus required to kill cells deficient in an interferon-mediated antiviral response relative to the amount needed to kill cells competent in an interferon-mediated antiviral response indicates that the virus being tested exhibits activity required for therapeutic utility in the treatment of neoplasms. Other NDV viruses and Sindbis virus are such natural occurring viruses that display tumor-selective killing (see Examples 21-23, and 25).

Table 1

## Naturally Occurring Viruses for Use in Cancer Therapy

| Virus Class            | Virus Family     | Virus Example                     |
|------------------------|------------------|-----------------------------------|
| RNA, negative stranded | Paramyxoviridae  | Newcastle Disease Virus           |
|                        |                  | Avian Paramyxovirus Type 2        |
|                        |                  | Measles                           |
|                        |                  | Mumps                             |
|                        |                  | Human Parainfluenza               |
|                        |                  |                                   |
|                        | Orthomyxoviridae | Influenza Virus                   |
|                        |                  |                                   |
|                        | Rhabdoviridae    | Vesicular Stomatitis Virus        |
|                        |                  |                                   |
| RNA, positive stranded | Togaviridae      | Sindbis Virus                     |
|                        |                  | Semliki Forest Virus              |
|                        |                  |                                   |
|                        | Flaviviridae     | Yellow fever (attenuated)         |
|                        |                  |                                   |
|                        | Picornaviridae   | Rhinovirus                        |
|                        |                  | Bovine enterovirus                |
|                        |                  |                                   |
|                        | Coronaviridae    | Avian infectious bronchitis virus |
|                        |                  | Human coronaviruses               |
|                        |                  |                                   |
| RNA, double stranded   | Reoviridae       | Reovirus                          |
|                        |                  | Rotavirus                         |
|                        |                  |                                   |
| DNA                    | Poxviridae       | Vaccinia virus                    |
|                        |                  |                                   |
|                        |                  |                                   |
|                        | Herpesviridae    | Herpes Simplex Virus, type I      |

***SUBSTITUTE SHEET (RULE 26)***

An understanding of the factors involved in the establishment of an antiviral state allows for the creation of a screening assay for tumors that are likely to respond to viral therapy. In principle, patient derived tumor tissue obtained from biopsy is screened for the expression of p68 kinase, p58, or other factors involved in the regulation of an antiviral state or cellular differentiation. Other factors include, but are not limited to, interferon response factor-1 (IRF-1), interferon stimulatory gene factor-3 (ISGF-3), c-Myc, c-Myb, and IFN receptors. In the case of c-Myc, c-Myb or p58, high level expression indicates that the tumor tissue or cells are treatment candidates for virus therapy. In the case of p68, IRF-1, ISGF-3, and IFN receptors, low level expression indicates that the tumor tissue or cells are treatment candidates for virus therapy.

At least 30% of human tumors are characterized by an activated Ras phenotype (Bos, J.L., 1989, Cancer res., 49:4682). An activated Ras phenotype can occur as a result of i) expression of Ras proteins with activating mutations, ii) overexpression of wild-type Ras protein or, iii) expression of unregulated tyrosine kinase receptors or other members of the Ras signaling pathway such as Grb2 or Sos. Cells with activated Ras phenotype have been shown to more sensitive to killing by NDV (Lorence, R.M., et al., 1994, Cancer Res., 54:6017-6021) and by reovirus (Strong, J.E.S., et al., 1998, EMBO, 17:3351-3362) than the same cells without an activated Ras phenotype. Activated Ras has been shown to inhibit the induction of responsive genes by interferon (Zullo, J.N., and Faller, D.V., 1988, Mol. Cell. Biol., 8:5080-5085) and the activation of PKR by dsRNA (Mundschau, L.J., and Faller, D.V., 1992, J. Biol. Chem., 267:23092-23098). Given the key role that PKR plays in the induction of the interferon-mediated antiviral response, the increased sensitivity of cells with an activated Ras phenotype to killing by NDV and reovirus provides even more evidence for the selective killing of cells deficient in an interferon-mediated antiviral response by viruses of the present invention.

Patient derived tumor tissue obtained from biopsy can be screened for the expression of i) activated Ras protein, ii) the GTP-bound fraction of Ras (active form), iii) activated form of MAPK (e.g., ERK1 or ERK2), or other indices of an activated Ras pathway. The presence of an activated Ras phenotype in the patient specimen indicates that tumor tissue is a treatment candidate for virus therapy.

In another embodiment of this invention, primary tumor tissue or cells obtained from patient biopsies are expanded in culture and tested for sensitivity to killing by a suitable viral therapy. In one embodiment, the amount of virus required to kill 50% of the tumor tissue

culture is compared to the amount required to kill 50% of a culture of normal cells as described above for the screening of candidate viruses. An increase of ten-fold or greater in the sensitivity of the tumor cells relative to normal cells to killing by the viral agent indicates that the tumor cells are specifically sensitive to the cytotoxic effects of the viral treatment. In a further embodiment of the invention, the ability of the targeted tumor cells to respond to endogenously or exogenously supplied IFN is determined by conducting the above screen in the presence of IFN (alpha or beta form, using e.g., 10 units per ml, see Example 27).

An understanding of the cellular receptors required for virus attachment or entry will allow additional screening for tumors that have high receptor expression and hence enhanced sensitivity to the interferon-sensitive virus. This is an additional level screening for patients that are likely to respond to virus therapy. Advantageously for therapy with an interferon-sensitive virus, the patient's tumor would be both resistant to interferon as well as having high expression of the cellular receptor for the virus. In principle, patient derived serum, tumor cells, tissues, or tissue sections are screened by immunoassay or immunostain for the amount of virus receptor present in the serum or on the tumor cells or tumor tissue. For example, Sindbis virus utilizes the high affinity laminin receptor to infect mammalian cells (Wang et al., 1992, J Virol., 66, 4992-5001). This same receptor is known to be expressed in higher amounts in many diverse types of metastatic cancer. The Panc-1 pancreatic cancer cell line, and the colon adenocarcinoma cell line SW620 are known to express a high level of high affinity laminin receptor mRNA (Campo et al, 1992, Am J Pathol 141:107301983; Yow et al., (1988) Proc. Natl Acad Sci, 85, 6394-6398) and are highly sensitive to Sindbis virus (Example 25). In contrast, the rectal adenocarcinoma cell line SW1463 is known to express very low levels of high affinity laminin receptor mRNA (Yow et al., (1988) Proc. Natl Acad Sci, 85, 6394-6398), and is more than 4 orders of magnitude more resistant to killing by PPSINDBIS-Ar339 than SW620 cells.

Existing strains of NDV, or other viruses including RNA and DNA viruses, are screened or engineered for altered IFN responses (e.g., advantageously increased IFN responses) in normal cells. In addition to the ability to elicit a strong IFN response, other viral characteristics are screened for or engineered into the virus. Viruses with altered receptor specificity (e.g., Sindbis virus PPSINDBIS-Ar339, see Example 25), or low neurovirulence are included in the subject invention (e.g., NDV virus PPNJROAKIN, see Example 24). Advantageously, viruses of the invention have the capacity to spread through direct cell to cell contact.

The invention described herein includes a broad group of viruses (see Table 1) that are useful for treatment of neoplasms in a manner analogous to the indication for NDV. In addition, viruses that naturally would not be candidates for use, due to the presence of a mechanism(s) to inactivate the IFN response in normal cells, are optionally engineered to circumvent the above restrictions. If left unmodified, viruses with mechanisms to inactivate the interferon response would be more toxic to normal cells than viruses with such mechanism removed. The subject invention provides (1) the development of a vector that can be easily manipulated; and (2) the creation of a set of therapeutic viruses. Manipulations include the addition of an IFN gene to permit the viral expression of a transgene expressing IFN, or other activators of the IFN response pathway. Additional permutations include the engineered expression of pro-drug activating enzymes such as the Herpesvirus thymidine kinase or cytosine deaminase (Blaese RM et al., 1994. Eur. J. Cancer 30A: 1190-1193) and the expression of suitable marker antigen to allow targeting of tumor cells by the immune system. An additional permutation include the engineered expression of receptor ligands to target cells with those receptors [e.g., expression of receptors to other viruses to target cells infected with those viruses (see Mebastsion et al., 1997, Cell 90:841-847; and Schnell MJ et al., 1997, Cell 90:849-857)].

Several Newcastle Disease virus strains in addition to the one cited above demonstrate selective killing of tumor cells. In a differential cytotoxicity assay using a second strain of mesogenic Newcastle Disease virus, tumor cells were found to be 3 orders of magnitude more sensitive than normal cells to killing by the virus (Example 21). Additionally, when a third mesogenic Newcastle Disease virus strain was used in a differential cytotoxicity assay, tumor cells were found to be 80 to 5000-fold more sensitive than normal cells to killing by the virus (Example 22). Both of these mesogenic Newcastle Disease virus strains also caused tumor growth regression following intratumoral administration to athymic mice bearing human tumor xenografts (Example 23).

In separate experiments, the safety of three distinct Newcastle Disease virus strains were studied following intracerebral inoculation in athymic and immune-competent mice. The results of this study showed that all three virus strains were well tolerated in mice with an intact immune system. Intracerebral inoculation into the brains of athymic mice revealed that one of the viruses was tolerated significantly better than the other two (Example 24). These results demonstrate that within a single virus family important differences in viral properties can occur and be can be exploited therapeutically for greater efficacy or increased safety.



Another means by which increased efficacy and lower toxicity following treatment with oncolytic viruses can be achieved is through the use of interferon-sensitive viruses that require specific cell surface receptors that are preferentially expressed on tumor cells. Sindbis virus provides an example of this type of restriction. Sindbis virus infects mammalian cells using the high affinity laminin receptor (Wang et al., (1992) J. Virol. 66, 4992-5001). When normal and tumor cells were infected with Sindbis virus in a differential cytotoxicity assay, cells which both were tumorigenic and expressed the high affinity laminin receptor were found to be more sensitive to killing by this virus than other cells (Example 25). Normal keratinocytes express the high affinity laminin receptor (Hand et al., (1985) Cancer Res., 45, 2713-2719), but were resistant to killing by Sindbis in this assay. Moreover, analysis of the interferon sensitivity and laminin receptor expression levels of normal keratinocytes and two different tumor cell lines demonstrates that PPSINDBIS-Ar339 selectively kills tumor cells that i) are deficient in an interferon-mediated antiviral response, and ii) express the high affinity laminin receptor.

PPSINDBIS-Ar339 also has potent tumor growth inhibitory properties when tested *in vivo* in athymic mice bearing subcutaneous SW620 adenocarcinoma tumors cells (Example 32).

Vesicular Stomatitis Virus (VSV) provides evidence for the generalized hypothesis of tumor-selective killing of by oncolytic viruses, i.e., an inherent deficiency in interferon responsiveness in tumor cells renders these cells sensitive to killing by interferon-sensitive replication-competent viruses. When VSV was used to infect non-tumorigenic human WISH cells and tumorigenic HT1080 or KB cells in the presence of exogenous interferon the tumorigenic cells were selectively killed (Example 26). Additional evidence is provided in Example 33. In this example, two unrelated viruses are shown to exhibit nearly identical behavior upon infection of a tumor cell line. The similar responsiveness of this cell line to each of these viruses demonstrates that the growth of the two unrelated viruses is controlled by similar mechanisms in this tumor cell line.

Below is a list of viruses that when modified to remove naturally-occurring anti-interferon activities, are useful for viral cancer therapy (see Table 2). Modified viruses (advantageously, but not necessarily, attenuated in addition to the anti-interferon modification, see Table 3) that have had endogenous anti-interferon activities destroyed or reduced, are useful for cancer therapy. This list includes, but is not be limited to, the viruses described below. Because of the similarity between viruses of a

common class, the identified mechanisms for each of the specific viruses listed below, are also present in other members of that class of virus as identical or functionally analogous mechanisms. The broader group of viruses is added in parenthesis. Viruses, such as those below, that have a functional loss of anti-interferon activity, through any means, including natural occurring mutations, as well as engineered deletions or point mutations, are useful in the methods of the subject invention.

Viruses that exercise more than one mechanism are optionally modified to contain mutations in one, some, or all of the activities. Mutations for some of the described activities are available in the general scientific community.

Isolates of naturally occurring or engineered virus that are slower growing, compared to the growth rate of wild-type virus, are particularly advantageous because a slower virus growth rate will allow a cell or population of cells competent in an interferon response to establish an efficient antiviral state before viral replication can kill the cell or cell population.

The disabling of viral anti-interferon activities as a specific alteration of viral character that results in the augmentation of the interferon response in an infected cell, but still allows viral replication in neoplastic cells is included in the subject invention.

Table 2 shows existing viruses engineered to remove anti-interferon activity.

Table 3 lists viruses engineered to be attenuated in virulence.

Table 2

## Extant Viruses Engineered to Remove Anti-IFN Activity

5

| Virus Class | Virus Family       | Virus            | Anti-IFN Activity       | Reference  |
|-------------|--------------------|------------------|-------------------------|--|
| RNA         | Reoviridae         | reovirus         | Omega-3                 | Imani and Jacobs (1988) Proc Natl Acad Sci USA 85:7887-7891. |
| DNA         | Poxviridae         | Vaccinia         | K3L                     | Beattle et al (1991) Virology 183-419                        |
|             |                    |                  | E3L                     | Beattle et al (1996) Virus Genes 12:89-94                    |
|             |                    |                  | B18R                    | Symons et al (1995) Cell 81:551-560                          |
|             | Adenoviridae       | Various subtypes | VA-1 transcripts        | Mathews and Shenk (1991) J Virol 64:5657-5662                |
|             | Alphaherpesviridae | HSV-1            | Gamma 34.5 gene product | Cho et al (1996) Proc Natl Acad Sci USA 92:10516-10520       |

Table 3

## Known Attenuating Mutations in Selected Viruses

| Virus Class | Virus Family       | Virus            | Attenuation   | Reference   |
|-------------|--------------------|------------------|---|---|
| RNA         | Reoviridae         | reovirus         | Omega-1   | Springs and Fields (1982) Nature 297:68-70              |
|             |                    | rotavirus        | Bovine strains (WC3)                                  | Clark (1988) J Infect Dis 158:570-587                   |
|             | Togaviridae        | Sindbis          | Attenuating mutations in the E1 and E2 coding regions | Polo and Johnston (1990) J Virol 64:4438-4444.          |
| DNA         | Poxviridae         | Vaccinia         | Vaccinia growth factor                                | Buller et al (1985) Virology 164:182                    |
|             |                    |                  | Thymidine kinase                                      | Buller et al (1985) Nature 317:813-815                  |
|             |                    |                  | Thymidylate kinase                                    | Hughes SJ et al (1991) J Biol Chem 266:20103-20109      |
|             |                    |                  | DNA ligase  | Kerr et al (1991) EMBO J 10:4343-4350                   |
|             |                    |                  | Ribonucleotide reductase                              | Child et al (1990) Virology 174:625-629                 |
|             |                    |                  | dUTPase   | Perkus et al (1991) Virology 180:406-410                |
|             | Adenoviridae       | Various subtypes | Ad-4, Ad-7 and Ad-21                                  | Takafugi et al (1979) J Infect Dis 140:48-53            |
|             | Alphaherpesviridae | HSV-1            | Thymidine kinase                                      | Field and Wildy (1978) J Hyg 81:267-277                 |
|             |                    |                  | Ribonucleotide Reductase                              | Goldstein and Weller (1988) Virology 166:41-51          |
|             |                    |                  | Gamma 34.5 gene product                               | Chou et al (1995) Proc Natl Acad Sci USA 92:10516-10520 |
|             |                    |                  | b'a'c' inverted repeats                               | Meigner et al (1988) J Infect Dis 162:313-322           |

**Treatment of Neoplasms**

The present invention relates to viral therapy of neoplasms, especially in animals having cancer. In an advantageous embodiment, the invention relates to the treatment of tumors which are 1 centimeter (cm) or more in size as measured in the greatest dimension. As used herein, "a 1 cm tumor" indicates that at least one dimension of the tumor is 1 cm in length. Such tumors are more sensitive than expected to viral therapy, often at least as sensitive to virus, if not more sensitive, than tumors which are smaller in size. In a more advantageous aspect of the invention, tumors greater than 1 cm. are treated, e.g., tumors which are 2 cm or greater, from about 2 cm to about 5 cm, and greater than 5 cm.

The present invention can also be employed to treat hosts having a high tumor burden. As used herein, the phrase "tumor burden" refers to the total amount of tumor within the body expressed as a percentage as body weight. Viral therapy of hosts having a tumor burden, e.g., from about 1% to about 2% of total body weight is surprisingly effective, e.g., producing tumor regression and a reduction in the overall tumor load. This is especially unexpected since a tumor burden of approximately 2% of the total body weight (e.g., a 1 kg tumor in a 60 kg human) is approximately the maximum cancer mass compatible with life. See, e.g., Cotran et al., In Robbins Pathological Basis of Diseases, 4th Edition, WB Saunders, 1989, page 252. In the Examples, volumes up to 397 mm<sup>3</sup> for a melanoma cancer (e.g., A375) in a mouse host showed complete regression in response to treatment with a Newcastle disease virus (e.g., a triple-plaque purified virus). Assuming that for tissue 1000 mm<sup>3</sup> equals 1 gram, a tumor having a volume of 397 mm<sup>3</sup> comprises approximately 2% of the total body weight for a 20 gram mouse.

As shown in Examples 4 to 9 below, tumor regression was achieved with tumors at least 1 cm in size, while untreated, control animals began dying from tumor burden within several weeks. Thus, such diseased animals were successfully treated despite being within two weeks of death. Thus, in accordance with the present invention, an animal which is near terminal from its tumor burden can be treated effectively with viral therapy. Consequently, the present invention can be used to treat patients who have not responded to conventional therapy, e.g., chemotherapy such as methotrexate, 5-fluorouracil, and radiation therapy.

The efficacy of NDV for the treatment of cancer following administration through the intraperitoneal route has also been examined. Using an ascites prevention model of ovarian cancer, intraperitoneal injection of NDV in mice harboring ES-2 human ovarian tumors resulted in increased survival compared to mice treated with saline (Example 16). When ES-

2 cells were used in an apparent ascites model, ascites fluid production was markedly decreased in virus-treated animals compared to saline controls (Example 17).

In another embodiment of the invention, the administration of virus results in 1) the relief of tumor related symptoms, such as but not limited to decreased rate of ascites fluid production, relief of pain, and relief of obstructive disease, and 2) the prolongation of life.

Fifty-two patients have received the plaque purified NDV isolate by the intravenous route. Treatment responses include: regressions of individual tumors in 5 patients; stabilization of disease in 2 patients for 7 months, in 2 patients for 5 months and in 1 more patient that is ongoing at 3 months; and a reduction in pain medication (Example 20).

### Administration and Formulation

In one embodiment of the invention, tumor cells or tissue are screened *in vitro* to determine those patients with tumors sensitive to the virus. Tumor cells removed from the patient (by methods such as fine needle aspiration for solid tumors or by paracentesis for ovarian ascites tumors) are grown *in vitro* and incubated with virus. In this embodiment of the invention, patients are selected for therapy if the virus has a high activity against their tumor cells.

In an advantageous embodiment of the invention, the amount of virus administered results in regression of the tumor or tumors. As used herein, the term "regression" means that the tumor shrinks, e.g., in size, mass, or volume. Shrinkage in tumor size is demonstrated by various methods, including physical examination, chest film or other x-ray, sonography, CT scan, MRI, or a radionucleotide scanning procedure.

Various types of neoplasms including cancers are treatable in accordance with the invention. The viruses of the present invention are useful to treat a variety of cancers, including but not limited to lung carcinoma, breast carcinoma, prostate carcinoma, colon adenocarcinoma, cervical carcinoma, endometrial carcinoma, ovarian carcinoma, bladder carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, melanoma, synovial sarcoma, neuroblastoma, lymphoma, leukemia, brain cancer including glioblastoma, neuroendocrine carcinoma, renal carcinoma, head and neck carcinoma, stomach carcinoma, esophageal carcinoma, vulvular carcinoma, sarcoma, skin cancer, thyroid pancreatic cancer, and mesothelioma. The viruses of the present invention are also useful to treat a variety of benign tumors, including but not limited to condylomas, papillomas, meningiomas, and adenomas.

A therapeutically effective amount of virus is administered to a host having a neoplasm. It is understood by those skilled in the art that the dose of virus administered will vary depending on the virus selected, type of neoplasm, the extent of neoplastic cell growth or metastasis, the biological site or body compartment of the neoplasm(s), the strain of virus, the route of administration, the schedule of administration, the mode of administration, and the identity of any other drugs or treatment being administered to the mammal, such as radiation, chemotherapy, or surgical treatment. These parameters are defined through maximum tolerated dose (MTD) determination in animal models and scaling to human dosage as a function of relative body surface area or body mass. It is also understood that under certain circumstances, more than one dose of the virus is given. The optimal interval between such multiple doses of the virus can be determined empirically and is within the skill of the art. NDV is generally administered from about  $3 \times 10^6$  to about  $5 \times 10^{12}$  PFU of virus. For local administration (e.g., directly into a tumor), total amounts of at least  $3 \times 10^6$  PFU, more advantageously at least  $3 \times 10^7$  PFU, more advantageously at least  $3 \times 10^8$  PFU, more advantageously at least  $3 \times 10^9$  PFU, more advantageously at least  $3 \times 10^{10}$  PFU, more advantageously at least  $3 \times 10^{11}$  PFU, and most advantageously at least  $5 \times 10^{12}$  PFU are typically used. For systemic administration, amounts of at least  $1 \times 10^8$  PFU of virus per square meter of body surface area, more advantageously at least  $1 \times 10^9$  PFU of virus per square meter of body surface area, more advantageously at least  $5.9 \times 10^9$  PFU of virus per square meter of body surface area, more advantageously at least  $1.2 \times 10^{10}$  PFU of virus per square meter of body surface area, more advantageously at least  $4.8 \times 10^{10}$  PFU of virus per square meter of body surface area, more advantageously at least  $7.2 \times 10^{10}$  PFU of virus per square meter of body surface area, and more advantageously at least  $9.6 \times 10^{10}$  PFU of virus per square meter of body surface area, and most advantageously at least  $3.0 \times 10^{11}$  PFU of virus per square meter of body surface area are used.

For intravenous administration, dosing schedules of once per week, two times per week and three times per week are used. A virus in accordance with the present invention, optionally with a chemotherapeutic agent, can be administered by various routes, e.g., enteral, parenteral, oral, nasal, rectal, intrathecal, intravenous (e.g., using a catheter), subcutaneous, intratumor (e.g., directly into its tissue or into vessels which perfuse it), peritumoral, local, sublingual, buccal, topical, intramuscular, by inhalation, percutaneous, vaginal, intra-arterial, intra-cranial, intradermal, epidural, systemically, topical, intraperitoneal, intrapleural,

intravesicular (for bladder tumors), etc. For lung tumors, a bronchial route (e.g., bronchial administration), a percutaneous route, or an endoscopic route can be used. Endoscopic injections of gastrointestinal tumors, as well as suppository treatments of rectal tumors are also used where appropriate.

5 Murine toxicity studies with NDV have indicated that the acute toxicity following intravenous virus administration is likely to be caused by cytokine mediated reactions. Cytokine responses to repeated stimuli are known to be desensitized, or down-regulated, following the initial induction event (Takahashi et al., (1991) Cancer Res. 51, 2366-2372). Mice receiving a desensitizing dose of virus tolerate subsequent administration of higher  
10 doses better than saline treated controls (Example 18). Mice intravenously injected with a desensitizing dose of virus were able to tolerate approximately 10-fold more virus on an second intravenous dose than mice receiving vehicle alone for the first injection.

The rate of virus administration by the intravenous route can significantly affect toxicity. Two groups of athymic mice were intravenously treated with identical doses of NDV which  
15 was administered either slowly (0.2 ml over 4 minutes) or rapidly (0.2 ml over 30 seconds). Comparison of the maximal weight loss in each group revealed 50% less weight loss in the group receiving slow injection versus a rapid injection (Example 19).

In the clinical trial, patients received three injections of the plaque purified NDV isolate over the course of one week. Under these conditions, a desensitizing effect of the initial dose  
20 lessened the toxicity associated with the second and third doses, even when the second and third doses are two to eight times higher than the first dose (Example 20). These data parallel those obtained with the animal studies shown in Examples 18 and 28. Furthermore in the clinical trial, higher rates of tumor regression were noted when higher doses were achievable using a smaller desensitizing dose (see Table 19, Example 20). This again paralleled the data  
25 obtained in animal model testing (Example 29).

One concern related to the use of oncolytic viruses in the treatment of cancer is the potential inhibitory effect the humoral immune response can exert on the therapy. In the clinical study, patients displaying stable disease after 1 month are eligible for a second course of treatment. The second, and subsequent courses of treatment are therefore administered in  
30 the presence of neutralizing antibodies to NDV. Nevertheless, infectious virus could be found in patients' urine after dosing for the second course and tumor regression was observed after a second course, providing evidence that administration of high doses of virus can overcome the effect of neutralizing antibodies and establish an infection within the patient



(Example 20). In an advantageous embodiment of the invention, multiple courses of virus therapy are administered. Examples of a course include: administering virus 3X per week for 1 week, followed by a 3 week rest period; administering virus 3X per week for 4 weeks, followed by a 2 week rest period; administering one dose of virus, followed a 4 week rest period; administering 3X per week for 6 weeks, followed by a 2 week rest period. In another embodiment, virus is administered more than 2 weeks after administration of the initial dose of virus.

In an advantageous embodiment of the invention, a desensitizing dose is given before higher subsequent doses. The desensitizing dose level is determined from clinical indicators of toxicity such as hypotension, fatigue, liver transaminase elevation or other appropriate indices, where the desensitizing dose level is equal to or below the maximum tolerated dose (MTD) for a single administration. Following desensitization, additional virus doses exceeding the desensitizing dose are given. In an advantageous embodiment, the subsequent virus doses are equal to or greater than the single dose MTD. For example, desensitizing virus doses of at least  $1 \times 10^8$  PFU/m<sup>2</sup>, more advantageously at least  $3 \times 10^8$  PFU/m<sup>2</sup>, more advantageously at least  $1 \times 10^9$  PFU/m<sup>2</sup>, more advantageously at least  $5.9 \times 10^9$  PFU/m<sup>2</sup>, and most advantageously at least  $1.2 \times 10^{10}$  PFU/m<sup>2</sup> are used. After desensitization, additional virus doses at least  $1 \times 10^8$  PFU/m<sup>2</sup>, more advantageously at least  $3 \times 10^8$  PFU/m<sup>2</sup>, more advantageously at least  $1 \times 10^9$  PFU/m<sup>2</sup>, more advantageously at least  $5.9 \times 10^9$  PFU/m<sup>2</sup>, more advantageously at least  $2.4 \times 10^{10}$  PFU/m<sup>2</sup>, more advantageously at least  $4.8 \times 10^{10}$  PFU/m<sup>2</sup>, and more advantageously at least  $9.6 \times 10^{10}$  PFU/m<sup>2</sup>, and most advantageously at least  $3.0 \times 10^{11}$  PFU/m<sup>2</sup> are used. In another embodiment, TNF $\alpha$ , IL-2, or other cytokines are administered, alone or in combination, for desensitization.

The time frame between doses including the time frame between desensitizing dose and the next dose is 1 to 14 days, advantageously 1 to 7 days. The desensitizing dose can be administered by various routes, e.g., intravenous, enteral, parenteral, oral, nasal, rectal, intrathecal, intravenous, subcutaneous, intratumor, peritumoral, local, sublingual, buccal, topical, intramuscular, by inhalation, percutaneous, vaginal, intra-arterial, intracranial, intradermal, epidural, systemically, topical, intraperitoneal, intrapleural, endoscopic, intrabronchial, etc. The subsequent doses can be administered by the same route as the desensitizing dose or by another route, e.g., intravenous, enteral, parenteral, oral, nasal, rectal, intrathecal, intravenous, subcutaneous, intratumor, peritumoral, local, sublingual, buccal, topical, intramuscular, by inhalation, percutaneous, vaginal, intra-arterial, intracranial,

intradermal, epidural, systemically, topical, intraperitoneal, intrapleural, endoscopic, intrabronchial, etc. The usefulness of IV desensitization for subsequent dosing by another route is demonstrated in Example 28. Mice intravenously injected with a desensitizing dose of virus were able to tolerate approximately 5-fold more virus on an intraperitoneal second dose than mice receiving vehicle alone for the first injection.

In preclinical testing, the increase in the maximum tolerated dose achievable using desensitization allowed for increased antitumor efficacy as described in Example 29.

Optionally, more than one route of administration can be used in either a sequential or concurrent mode. Routes for either concurrent or sequential administration include but are not limited to intravenous, enteral, parenteral, oral, nasal, rectal, intrathecal, intravenous, subcutaneous, intratumor, peritumoral, local, sublingual, buccal, topical, intramuscular, by inhalation, percutaneous, vaginal, intra-arterial, intracranial, intradermal, epidural, systemically, topical, intraperitoneal, intrapleural, endoscopic, intrabronchial, etc. An example would be the administration of a intravenous desensitizing dose followed by an intraperitoneal dose.

In another advantageous embodiment of the invention, the virus is administered by slow infusion including using an intravenous pump, syringe pump, intravenous drip or slow injection over the course of 4 minutes to 24 hours, advantageously between 20 and 60 minutes.

A virus, and optionally one or more chemotherapeutic agents, is administered by a single injection, by multiple injections, or continuously. The virus is administered before, at the same time, or after the administration of chemotherapeutic agents (such as but not limited to: busulfan, cyclophosphamide, methotrexate, cytarabine, bleomycin, platinum coordination complex such as carboplatin or cisplatin, doxorubicin, dacarbazine, gemcitabine, melphalan, mercaptopurine, vinblastine, 5-fluorouracil, taxol, and retinoic acid). Viral therapy in accordance with the present invention is optionally combined with other treatments, including, surgery, radiation, chemotherapy (see, e.g., Current Medical Diagnosis and Treatment, Ed. Tierney et al., Appleton & Lange, 1997, especially pages 78-94), and biological therapy. The virus is administered before, at the same time, or after the administration of biological agents such as (1) other oncolytic agents [such as but not limited to: adenoviruses with one of its genes under transcriptional control of a prostate cell specific response element (see Rodriques, R. et al, 1997, Cancer Res, 57:2559-2563; adenoviruses which do not encode a Elb polypeptide capable of binding p53 (see Bischoff, J.R., et al,

1996, Science 274:373-376); a herpes simplex virus that is incapable of expressing a functional gamma 34.5 gene product (see Mineta, T. et al, 1995, Nature Medicine, 1:938-943)]; (2) cytokines (such as but not limited to: colony stimulating factors such as GM-CSF; tumor necrosis factor, and interleukins such as IL-1, IL-2, IL-6 and IL-10); (3) viral vectors [such as but not limited to adenovirus encoding p53 (see Zhang, WW et al, 1994, Cancer Gene Therapy, 1:5-13)]; and (4) cancer vaccines.

In one embodiment of the invention, therapy consists of the serial treatment with antigenically distinct viruses which are cytotoxic and tumor selective via the IFN mechanism. This embodiment allows viral therapy over an extended period without immunological interference.

Another embodiment involves the treatment of patients with IFN (e.g.  $\alpha$ IFN,  $\beta$ IFN or  $\gamma$ IFN) prior to, concurrent with, or following administration of NDV (or other virus). The IFN is selected from the group class I (alpha, beta and omega) and class II (gamma), and recombinant version and analogs thereof as discussed in, for example, Sreevalsoun, T., 1995 (In: Biologic Therapy of Cancer, second edition, edited by V.T. DeVita, Jr., S. Hellman, and S.A. Rosenberg, J.B. Lippincott Company, Philadelphia, pp347-364). Normal cells respond to the IFN pre-treatment with an augmented IFN response to viral infection affording even greater safety to these cells. Tumor cells deficient in the IFN signaling pathway remain sensitive to killing by the virus. This allows even higher doses of viral therapy to be used. The IFN is administered in accordance with standard clinical guidelines for doses and regimens known to be effective for treating viral infections.

In another embodiment of the invention, other drugs, known to affect the IFN response pathway are also optionally used to increase the sensitivity of tumor cells, or increase the resistance of normal cells to the cytotoxic effects of viral infection. This class of drugs includes, but is not limited to tyrosine kinase inhibitors, cimetidine, and mitochondrial inhibitors. One strategy for enhancing oncolytic activity of therapeutic viruses of the invention involves disruption of mitochondrial oxidative phosphorylation. Preferred agents are clinically acceptable drugs that inhibit respiratory chain function or mitochondrial protein synthesis. 4-quinolone antibiotics, menadione, chloramphenicol, chloroquine, and tetracyclines are useful for potentiating oncolytic activity of anticancer viruses. Such agents are administered in clinically tolerated doses 0 to 24 hours prior to administration of an oncolytic virus. Mitochondrial inhibitors are also optionally administered after the virus to further sensitize tumors supporting viral replication.

Hypoxia and hyperthermia are also known to modulate interferon responsiveness. Therefore, in one embodiment of the invention, hypoxic regions of tumors are oxygenated prior to or during exposure of tumors to a therapeutic oncolytic virus. Methods for accomplishing this include, but are not limited to, systemic administration of oxygenated fluorocarbon blood hemoglobin substitutes, erythropoietin, or vasodilators. Tumor oxygenation is also accomplished by delivering oxygen at supranormal concentrations in air via the lungs.

In another embodiment of the invention, immunosuppressants such as cyclosporin A, azathiaprime, leflunomide, anti-CD-40 ligand antibodies (Foy, T.M., et al., 1993, J. Exp. Med. 178:1567-1575) and various corticosteroid preparations such as, cortisol, predisone, prednisolone, 6 $\alpha$ -methylprednisolone, fludrocortisone, corticosterone, triamcinolone, paramethasone, betamethasoneand, and dexamethasone are administered before, during, or after administration of the virus. Alternatively, immunostimulatory compound, e.g., lipopeptides, can be administered with the virus.

In another embodiment of the invention, agents which inhibit TNF-alpha activity such as antibodies against TNF-alpha (see Example 30), soluble TNF-alpha receptors, corticosteroids, or other compounds, are administered before, during or after the virus.

An independent mechanism by which the amount of interferon produced in response to viral infection is increased through the use of nucleosides (Machida, H., 1979. Microbiol. Immunol. 23:643-650), nucleoside precursors, or drugs that increase the cellular concentration of one or more nucleosides, are optionally used as an adjunct to viral therapy.

Certain purine nucleoside analogs, e.g., 2-chlorodeoxyadenosine and 2'-deoxycoformycin, reduce interferon production in vivo. Such compounds are used to further effect differences in interferon sensitivities of tumor cells versus normal cells and are optionally used as an adjunct to viral therapy.

In one aspect, an effective amount of virus can be subdivided into smaller dose units and injected at the same time into different locations of the same tumor. For continuous administration, the desired agent(s) is administered via an implanted minipump or it is impregnated into a desired polymer and then transplanted into a desired location (e.g., directly into the tumor) for slow or delayed release.

A virus of the present invention is formulated as a pharmaceutical preparation by bringing it into a suitable dose form, together with at least one excipient or auxiliary, and, if desired, with one or more further active compounds. The preparations are utilized in both human and

veterinary medicine. Suitable excipients include, e.g., organic and inorganic substances which are appropriate for enteral or parenteral administration, e.g., water, saline, tissue culture media, buffers, lysine, citrate, glycerol triacetate and other fatty acid glycerides, gelatin, soya lecithin, carbohydrates such as, mannitol, sucrose, lactose or starch, magnesium stearate, talc, cellulose or protein carriers, or a combination of the preceding compounds, such as mannitol/lysine, or mannitol/lysine/sucrose. The preparations are sterilized and/or contain additives, such as preservatives or stabilizers. For parenteral administration, e.g., systemic or local injection, a virus preparation is formulated, e.g., as an aqueous suspension or emulsion.

The invention also relates to a method of treating a disease in a mammal, in which the diseased cells have defects in an interferon-mediated antiviral response, comprising administering to the mammal a therapeutically effective amount of an interferon-sensitive, replication-competent, clonal virus. For example, many viruses have evolved mechanisms to ablate the interferon-mediated antiviral response of the host cell. The hepatitis B and hepatitis C viruses are leading causes of liver dysfunction worldwide. These viruses are associated with progressive liver damage, cirrhosis, and hepatocellular carcinoma. Treatment with interferons is the current standard therapy for these diseases, but large segments of the population fail to respond to treatment, or suffer relapses following termination of therapy. The terminal protein of the hepatitis B virus (HBV) has been shown to inhibit the cellular responses to interferon, and double-stranded RNA, a known activator of PKR (Foster, G.R., et al., 1991, Proc. Natl. Acad. Sci., USA, 88:2888-2892). Additionally, the core antigen of HBV has been shown to inhibit the expression of the beta interferon gene (Whitten, T.M., et al., 1991, J Virol., 65:4699-4704), and the HBV-associated delta agent has been shown to block the activity of PKR in rabbit reticulolysates (Robertson, H.D., et al., 1996, J Virol., 70:5611-5617). The hepatitis C virus (HCV) also possesses an activity that represses the PKR protein kinase. The NS5A protein of HCV has been shown to directly inhibit PKR protein kinase activity (Gale, M.J., et al., 1998, Clin. Diagn. Virol., 10:157-162). Patients failing initial interferon therapy for HBV or HCV infection are candidates for treatment with viruses of the current invention. The therapeutic virus, or viruses, are administered by any of the means described above, but would be advantageously administered intravenously or through the intrahepatic artery

There is evidence that human immunodeficiency virus (HIV) infected cells are also resistant to the effects of interferon, and that resistance is correlated with the presence of

AIDS (Kunzi, M.S., et al., 1995, J. Infect. Dis., 171:822-828; Edlin B.R., et al., 1992, Ann. Intern. Med., 117:457-460). Mechanistically, the TAR RNA region of HIV has been shown to interact with PKR and either activate or inhibit the activity of the kinase dependent on the concentration of TAR RNA (Maitra, R.K., et al., 1994, Virology, 204:823-827).

5 Additionally, the cellular TRBP and the viral Tat proteins are known to bind to the HIV TAR RNA region and inhibit the activity of PKR (Davies, P.H., et al., 1994, Proc. Natl. Acad. Sci., 91:4713-4717; Brand, S.R., et al., 1997, J. Biol. Chem., 272:8388-8395). Cells infected with HIV and resistant to the effects of interferon are targets for killing by the viruses of this invention.

10 A number of other human viral pathogens are known to inhibit one or more components of the interferon-mediated antiviral state. Adenovirus and Epstein-Barr virus are all known to express abundant, small RNA species that block the activation of PKR in infected cells (for a review see Clemens, M.J., et al., 1994, Biochimie, 76:770-778). Epstein-Barr virus is nearly 100% associated with endemic Burkitt's lymphoma, in addition to poorly and  
15 undifferentiated nasopharyngeal carcinoma, and is the causative agent of infectious mononucleosis. Vaccinia virus has been shown to encode proteins, E3L and K3L, that block the activation of PKR and serve as false substrate for activated PKR kinase, respectively (Davies, M.V., 1993, J. Virol., 67:1688-1692). The E3L protein has also been shown to inhibit the 2'-5' synthetase component of the cellular antiviral response (Rivas, C., et al.,  
20 1998, Virology, 243:406-414).

A homolog of the vaccinia virus E3L protein has also been described in a human orf parapoxvirus (McInnes, C.J., 1998, Virus Genes, 17:107-115). Vaccinia virus also encodes a soluble form of the type I interferon receptor that inhibits the induction of an antiviral state by interferon (Symons, J. A., 1995, Cell, 81:551-560). A cellular inhibitor of the PKR kinase is  
25 induced in cells infected with influenza virus (Lee, T.G., et. Al., 1990, Proc. Natl. Acad. Sci. USA, 87:6208-6212) or poliovirus (Black, T.L., et al., 1989, J. Virol., 63:2244-2251). Herpes simplex 1 virus also encodes a protein (gamma 34.5) that antagonizes the PKR mediated shut-off of protein synthesis in infected cells (Chou, J. et al., 1995, Proc. Natl. Acad. Sci. USA, 92:10516-10520). The NS1 protein of influenza virus and the sigma 3  
30 protein of reovirus have been shown to inhibit the activation of PKR by double-stranded RNA (Lu, Y., et al., 1995, Virology, 214:222-228; Imani, F. and Jacobs, B.L., 1988, Proc. Natl. Acad. Sci. USA, 85:7887-7891). In each of the above examples of viral interference

with the cellular establishment of an antiviral state, treatment of infected cells with the viruses of the present invention leads to the selective killing of the infected cells.

Unless indicated otherwise herein, details and conditions of viral therapy of this invention are in accordance with US Application Serial No. 08/260,536 whose disclosure is incorporated herein by reference in its entirety. The entire disclosure of all applications, patents and publications, cited above and in the figures are hereby incorporated by reference.

\* \* \*

The following examples are illustrative, but not limiting of the methods and compositions of the present invention. Other suitable modifications and adaptations of a variety of conditions and parameters normally encountered in clinical therapy which are obvious to those skilled in the art are within the spirit and scope of this invention.

### Example 1

**PPMK107, (a triple plaque purified isolate of the NDV strain MK107) demonstrates a selective cytotoxic activity toward many human cancer cells compared to normal human cells.**

Human tumor cells and normal cells were grown to approximately 80% confluence in 24 well tissue culture dishes. Growth medium was removed and PPMK107 was added in 10 fold dilutions ranging from  $10^6$  plaque forming units (PFU)/well to  $10^{-1}$  PFU/well. Controls wells with no virus added were included on each plate. Virus was adsorbed for 90 minutes on a rocking platform at  $37^{\circ}\text{C}$ . At the end of the incubation period, the viral dilutions were removed and replaced by 1 ml of growth medium. Plates were then incubated for 5 days at  $37^{\circ}\text{C}$  in 5%  $\text{CO}_2$ , then assessed qualitatively for the amount of cytopathic effect (CPE). Cytotoxicity was quantified by using a colorimetric MTT (2-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Cell Titer 96, catalog #G4000, Promega Corporation, Madison WI 53711) monitored at 570 nm, that detects mitochondrial enzyme activity (Mosman, T., 1983, J. Immunol. Methods 65:55). The viability in the virus treated wells was expressed as a percent of the activity in untreated control wells. The data was plotted graphically as PFU/well vs. viability as a percent of control. The  $\text{IC}_{50}$  was calculated as the amount of virus in PFU/well causing a 50% reduction in the amount of viable cells.

The results are given in Tables 4, 5 and 6. PPMK107 demonstrated a high degree of cytotoxic activity against a diverse set of human cancer cells with 30 out of 39 malignant lines having an  $\text{IC}_{50}$  value less than 1000 compared to the relative insensitivity of normal

human cell types. The majority of human cancer cells had IC<sub>50</sub> values that were 2 to 3 orders of magnitude lower than most normal human cell types.

**Table 4**  
**Summary of Cytotoxicity Results**

| TUMOR TYPE                      | CELL LINE            | IC-50 (PFU/ml) |
|---------------------------------|----------------------|----------------|
| FIBROSARCOMA                    | HT1080               | 2              |
| PANCREATIC CARCINOMA            | PANC-1               | 3              |
| RENAL CARCINOMA                 | CAKI-1               | 8              |
|                                 | CAKI-2               | 11             |
|                                 | A498                 | 15             |
| LUNG CARCINOMA (Non-small cell) | H-1299 (low passage) | 26             |
|                                 | A427                 | 2              |
|                                 | A549                 | 13             |
| MELANOMA                        | SKMEL2               | 8              |
|                                 | SKMEL3               | 2              |
|                                 | SKMEL5               | 4              |
|                                 | A375                 | 37             |
|                                 | MALME-3M             | 778            |
|                                 | HT144                | 28             |
| BREAST CARCINOMA                | SKBR3                | 10             |
|                                 | MDA-MB-468           | 44             |
|                                 | ZR75-1               | 78             |
| OVARIAN CARCINOMA               | SW626                | 4              |
|                                 | PA-1                 | 4              |
|                                 | ES-2                 | 13             |
|                                 | SKOV-3               | 24             |
|                                 | OVCAR3               | 34             |
| GLIOBLASTOMA                    | U87MG                | 25             |
|                                 | U373MG               | 765            |
|                                 | U138                 | 38             |
|                                 | A172                 | 207            |
| BLADDER CARCINOMA               | HT1197               | 3              |
|                                 | UM-UC-3              | 54             |
|                                 | HT1376               | 422            |
| NEUROBLASTOMA                   | IMR-32               | 41             |



|                                 |          |            |
|---------------------------------|----------|------------|
| CERVICAL CARCINOMA              | HeLa     | 4          |
| PROSTATE CARCINOMA              | DU-145   | 31         |
|                                 | PC3      | 3.1 E+03   |
| COLON CARCINOMA                 | SW620    | 55         |
|                                 | HT29     | > 1.0 E+06 |
| HEAD AND NECK CARCINOMA         | KB       | 4          |
|                                 | A253     | 2.7 E+03   |
|                                 | FaDu     | 2.9 E+03   |
|                                 | Hep-2    | 1.5 E+04   |
| NEUROEPITHELIOMA                | SK-N-MC  | 20         |
| SMALL CELL CARCINOMA (Lung)     | DMS-114  | 48         |
|                                 | DMS-153  | 1.1 E+05   |
|                                 | NCI-H345 | 1.2 E+06   |
| SMALL CELL CARCINOMA (Prostate) | NCI-H660 | 1.0 E+05   |
| LEUKEMIA (AML)                  | K562     | 5.4 E+04   |
| LYMPHOMA (Burkitt's)            | Ramos    | > 1.0 E+06 |
|                                 | Daudi    | > 1.0 E+06 |

Table 5. Summary of Cytotoxicity Assay Results Using Normal Human Cells.

| Cell Type    | Cell    | IC <sub>50</sub> (PFU/well) |
|--------------|---------|-----------------------------|
| Keratinocyte | NHEK    | 9.0 x 10 <sup>6</sup>       |
| Fibroblast   | CCD-922 | 1.4 x 10 <sup>5</sup>       |
|              | NHDF    | 8.1 x 10 <sup>3</sup>       |
| Endothelial  | HPAEC   | 5.2 x 10 <sup>4</sup>       |
| Renal        | RPTEC   | 2.7 x 10 <sup>4</sup>       |
| Melanocyte   | NHEM    | 5.1 x 10 <sup>4</sup>       |
| Astrocyte    | NHA     | 3.8 x 10 <sup>3</sup>       |

**Table 6. Summary of Cytotoxicity Assay Results Using Rapidly Proliferating Normal Human Cells.**

| Cell Type   | Rate of Proliferation |                   | IC <sub>50</sub> (PFU/well) |
|---|-----------------------|-------------------|-----------------------------|
|   | In vitro              | In vivo           |                             |
| Bone Marrow Cells,<br>CD34 <sup>+</sup> Enriched to 50% | Moderate to High      | High              | 6.2 x 10 <sup>3</sup>       |
| Breast Epithelial Cells                                 | Very low <sup>a</sup> | High <sup>a</sup> | 30                          |

<sup>a</sup> — Human breast epithelial cells tested (HMEC) had a high rate of proliferation after stimulation with bovine pituitary extract and human epidermal growth factor. In marked contrast, normal breast epithelial cells almost always have a very low degree of proliferation in adult women with cancer.

### **Example 2**

#### **Use of PPMK107 for the Intratumoral Treatment of Human Tumor Xenografts (<10 mm and >5 mm) in Athymic Mice.**

Athymic mice were injected intradermally with 10 million human tumor cells. After tumors reached a size range from between 5 and 10 mm, a single injection of PPMK107 (at a dose of 3 x 10<sup>8</sup> PFU) or saline was given. Almost all tumor types exhibited a rate of complete or partial regression of 50% to 100% (see Table 7) in mice treated with PPMK107. The one exception is the case of the U87MG experiment (experiment I): Although only one of 9 tumors treated with PPMK107 completely regressed, two more virus-treated tumors showed regression of 32% and 20% and two more virus-treated tumors had slower growth than all 8 tumors treated with saline control. Tumor regression was virtually absent in the saline control treated tumors: In all of these experiments (A through I listed in Table 7) only one of 73 control tumors showed regression. These results indicate that diverse tumor types showed responses to intratumoral PPMK107 treatment.

To examine virus replication within the tumor, immunohistochemical staining for viral antigen (using a monoclonal antibody against the NDV P protein) was performed using the subcutaneous HT1080 fibrosarcoma model. Within 30 minutes of intratumoral injection of 3 x 10<sup>8</sup> PFU of PPMK107, the tumor tissue was negative for viral antigen. However, by day 2 post treatment, intense immunostaining for viral antigen was seen within the tumor, indicating virus replication within the tumor. Importantly, virus replication was specific for

the tumor tissue since the neighboring connective tissue and skin was negative for viral antigen.

**Table 7. PPMK107 Intratumoral Treatment of Subcutaneous Human Tumor Xenografts (<10 mm and >5 mm) in Athymic Mice.**

| Tumor  | Tumor Type        | Expt # | Dose       | N  | Complete Regression | Complete + Partial Regression |
|--------|-------------------|--------|------------|----|---------------------|-------------------------------|
| HT1080 | Fibrosarcoma      | A      | 3.00E + 08 | 12 | 11                  | 11                            |
|        |                   | B      | 3.00E + 08 | 9  | 8                   | 8                             |
|        |                   | B      | 3.00E + 08 | 8  | 8                   | 8                             |
| PA-1   | Ovarian Carcinoma | D      | 3.00E + 08 | 9  | 9                   | 9                             |
| KB     | Oral Carcinoma    | E      | 3.00E + 08 | 12 | 7                   | 10                            |
| SKMEL5 | Melanoma          | F      | 3.00E + 08 | 8  | 5                   | 7                             |
| A375   | Melanoma          | G      | 3.00E + 08 | 8  | 5                   | 7                             |
|        |                   | H      | 3.00E + 08 | 1  | 1                   | 4                             |
| U87Mg  | Glioblastoma      | I      | 3.00E + 08 | 9  | 1                   | 1                             |

### Example 3

**Use of PPMK107 for the Intravenous Treatment of Human Tumor Xenografts (<8.5 mm and >5.5 mm) in Athymic Mice.**

Athymic mice were injected intradermally with 10 million human HT1080 fibrosarcoma cells. After tumors reached a size range from between 5 and 8 mm, a intravenous injection(s) of PPMK107 or saline were made. As shown in Table 8, at the highest virus dose level (1 x

10<sup>9</sup> PFU) complete tumor regression was seen in all seven mice. Single injections of  $3 \times 10^8$  and  $6 \times 10^7$  resulted in regression rates of over 90%. While a single IV injection of  $3 \times 10^8$  gave only a 55% rate of tumor regression, three IV injections at this dose level yielded a 100% rate of response. Mice treated with IV saline exhibited no evidence of tumor regression. These results indicate that subcutaneous HT1080 tumors are very responsive to IV treatment with PPMK107.

**Table 8. PPMK107 Intravenous Treatment of Subcutaneous Human HT1080 Fibrosarcoma Xenografts (<8.5 mm and >5.5 mm) in Athymic Mice.**

| Dose        | Schedule                         | N  | Complete Regression | Complete + Partial Regression | % Regression |
|-------------|----------------------------------|----|---------------------|-------------------------------|--------------|
| 1.00 E + 09 | One Injection                    | 7  | 7                   | 7                             | 100%         |
| 3.00E + 08  | One Injection                    | 10 | 9                   | 10                            | 100%         |
| 6.00E + 07  | One Injection                    | 11 | 10                  | 10                            | 91%          |
| 2.00E + 07  | One Injection                    | 11 | 5                   | 6                             | 55%          |
| 2.00E + 07  | Three Injections every other day | 7  | 5                   | 7                             | 100%         |
| Saline      | One Injection                    | 10 | 0                   | 0                             | 0%           |
| Saline      | Three Injections Every Other Day | 6  | 0                   | 0                             | 0%           |

**Example 4****First Experiment Using PPMK107 for Intratumoral Treatment of Large A375 Melanoma Xenografts in Athymic Mice**

5        Athymic mice were injected intradermally with 10 million A375 human melanoma cells. Ten days later, tumors of various sizes were treated with a single injection PPMK107 (doses of  $3 \times 10^8$ ,  $9 \times 10^8$ , and  $1.5 \times 10^9$  PFU) or saline. For those tumor with a single largest dimension of 10 to 11 mm, all nine completely regressed in response to intratumoral treatment with these doses of PPMK107, while of those tumors with a single largest  
10        dimension of 8 to 9.5 mm, twelve out of 24 completely regressed in response to virus therapy ( $P < 0.008$ ; Table 9, section A). No tumor regression was seen in any mouse treated with saline.

      These same tumors when sorted by tumor volume also indicated a high percentage of complete regression in those of larger tumor volume. In response to these doses PPMK107,  
15        complete regression occurred in 14 out of 17 tumors with volumes  $> 300 \text{ mm}^3$  (range of 304 to  $397 \text{ mm}^3$ ) and in 7 out of 16 tumors with volumes  $< 300 \text{ mm}^3$  (range of 144 to 295;  $P < 0.023$ ; Table 9, section B).

      These results indicate that tumors at least 1 cm in length or  $300 \text{ mm}^3$  in volume were at least as sensitive, if not more sensitive, to intratumoral PPMK107 treatment than smaller  
20        tumors.

**Table 9. Intratumoral PPMK107 Treatment of Intradermal A375 Melanoma Xenografts.**

| <b>A. Tumors Sorted Based on the Single Largest Dimension</b> |                   |  |                                |          |  |                                |                   |
|---|-------------------|--|--------------------------------|----------|--|--------------------------------|-------------------|
|   |                   | <b>Tumor Dimension: 8 to 9.5 mm</b>          |                                |          | <b>Tumor Dimension: 10 to 11 mm</b>          |                                |                   |
| <b>Treat<br/>ment</b>   | <b>Dosage</b>     |  | <b>Complete<br/>Regression</b> | <b>%</b> | <b>N</b>                                     | <b>Complete<br/>Regression</b> | <b>%</b>          |
| PPMK107   | $1.5 \times 10^9$ | 8  | 2                              | 25%      | 3  | 3                              | 100%              |
| PPMK107   | $9.0 \times 10^8$ | 8  | 7                              | 88%      | 3  | 3                              | 100%              |
| PPMK107   | $3.0 \times 10^8$ | 8  | 3                              | 38%      | 3  | 3                              | 100%              |
| Total   |                   | 24   | 12                             | 50%      | 9  | 9                              | 100% <sup>a</sup> |
| Saline  |                   | 6  | 0                              | 0%       | 0  |                                | 0%                |
| <b>B. Tumors sorted Based on the Tumor Volume</b>             |                   |  |                                |          |  |                                |                   |
|   |                   | <b>Tumor Volume: &lt; 300 mm<sup>3</sup></b> |                                |          | <b>Tumor Volume: &gt; 300 mm<sup>3</sup></b> |                                |                   |
| <b>Treat<br/>ment</b>   | <b>Dosage</b>     |  | <b>Complete<br/>Regression</b> | <b>%</b> | <b>N</b>                                     | <b>Complete<br/>Regression</b> | <b>%</b>          |
| PPMK107   | $1.5 \times 10^9$ | 6  | 2                              | 33%      | 5  | 3                              | 60%               |
| PPMK107   | $9.0 \times 10^8$ | 4  | 3                              | 75%      | 7  | 7                              | 100%              |
| PPMK107   | $3.0 \times 10^8$ | 6  | 2                              | 33%      | 5  | 4                              | 80%               |
| Total   |                   | 16   | 7                              | 44%      | 17   | 14                             | 82% <sup>b</sup>  |
| Saline  |                   | 8  | 0                              | 0%       | 1  | 0                              | 0%                |

<sup>a</sup>-  $P < 0.008$  for complete regression in the PPMK107 10 to 11 mm group versus the PPMK107 8 to 9.5 mm treated group.

<sup>b</sup>-  $P < 0.023$  for complete regression in the PPMK107-treated >300 mm<sup>3</sup> group versus the PPMK107-treated <300 mm<sup>3</sup> PPMK107-treated group

**Example 5****Second Experiment Using PPMK107 for Intratumoral Treatment of Large A375 Melanoma Xenografts in Athymic Mice.**

5 Tumors were established as in Example 4 ten days after tumor cell inoculation. Treatment consisted of various doses of PPMK107 ( $3 \times 10^6$  PFU,  $3 \times 10^7$ ,  $3 \times 10^8$ , and  $1.5 \times 10^9$ ) or saline. For tumors 10 to 11.5 mm in single largest dimension, complete or partial (at least 50%) regression occurred in all 28 tumors treated with PPMK107 using these doses in contrast to no regression in any of the saline-treated mice (Table 10, section A).

10 When these same tumors were sorted by tumor volume, all 26 tumors greater than  $300 \text{ mm}^3$  (range: 309 to  $525 \text{ mm}^3$ ) regressed completely or partially (at least 50%) in response to PPMK107 in contrast to none of the saline treated mice (Table 10, section B).

These results confirm that tumors at least 1 cm in length or  $300 \text{ mm}^3$  in volume are sensitive to intratumoral PPMK107 treatment.

**Table 10. Intratumoral PPMK107 Treatment of Intradermal A375 Melanoma Xenografts.**

| <b>A. Tumors 10 to 11.5 mm (sorted Based on the Single Largest Dimension)</b> |                       |          |                 |          |                               |          |
|---|-----------------------|----------|-----------------|----------|-------------------------------|----------|
| <b>Tx</b>   | <b>Dose</b>           |          | <b>Complete</b> | <b>%</b> | <b>Complete +<br/>Partial</b> | <b>%</b> |
|   | 1.5 x 10 <sup>9</sup> | 7        | 7               | 100%     | 7                             | 100%     |
|   | 3.0 x 10 <sup>8</sup> | 7        | 6               | 86%      | 7                             | 100%     |
|   | 3.0 x 10 <sup>7</sup> | 7        | 5               | 71%      | 7                             | 100%     |
|   | 3.0 x 10 <sup>6</sup> | 7        | 5               | 71%      | 7                             | 100%     |
|   | All PPMK107 Groups    | 28       | 23              | 82%      | 28                            | 100%     |
|   | Saline                | 6        | 0               | 0%       | 0                             | 0%       |
| <b>B. Tumors &gt; 300 mm<sup>3</sup> (sorted Based on the Tumor Volume)</b>   |                       |          |                 |          |                               |          |
| <b>Tx</b>   | <b>Dose</b>           | <b>N</b> | <b>Complete</b> | <b>%</b> | <b>Complete +<br/>Partial</b> | <b>%</b> |
|   | 1.5 x 10 <sup>9</sup> | 7        | 7               | 100%     | 7                             | 100%     |
|   | 3.0 x 10 <sup>8</sup> | 7        | 6               | 86%      | 7                             | 100%     |
|   | 3.0 x 10 <sup>7</sup> | 6        | 4               | 67%      | 6                             | 100%     |
|   | 3.0 x 10 <sup>6</sup> | 6        | 4               | 67%      | 6                             | 100%     |
|   | All PPMK107 Groups    | 26       | 21              | 81%      | 26                            | 100%     |
|   | Saline                | 5        | 0               | 0%       | 0                             | 0%       |

5

**Example 6****Third Experiment Using PPMK107 for Intratumoral Treatment of Large A375 Melanoma Xenografts in Athymic Mice.**

Tumors were established as in Example 4 nineteen days after tumor cell inoculation. Intratumoral treatment consisted of various doses of PPMK107 (3 x 10<sup>8</sup>, 3 x 10<sup>6</sup>, 3 x 10<sup>5</sup>, 3 x 10<sup>4</sup>, 3 x 10<sup>3</sup>, 3 x 10<sup>2</sup> PFU) or saline. For tumors 12.5 to 14 mm in single largest dimension

10



(volume range: 632 to 787 mm<sup>3</sup>; average volume 698 mm<sup>3</sup>), tumor regressions of at least 50% occurred in two out of three mice treated with  $3 \times 10^8$  PFU in contrast to no regression in both saline-treated mice (Table 11). Using the same dose of PPMK107 ( $3 \times 10^8$  PFU) to treat tumors with a single largest dimension of 10 to 12 mm (volume range: 320 to 600 mm<sup>3</sup>; average volume: 411 mm<sup>3</sup>), seven of 8 mice exhibited regression of at least 25% ( $P < 0.001$  for regression of at least 25% compared to the saline treated mice which exhibited no regressions, Table 11). Regressions of at least 25% for tumors of length 10 to 12 mm tumors were also seen in mice treated with  $3 \times 10^6$  PFU,  $3 \times 10^5$  PFU,  $3 \times 10^4$  PFU, and  $3 \times 10^3$  PFU, but not for mice treated with  $3 \times 10^2$  PFU or saline (Table 11).

These results confirm that tumors at least 1 cm in length or 300 mm<sup>3</sup> in volume are sensitive to intratumoral PPMK107 treatment.

Table 11. Third Experiment Using PPMK107 for the Intratumoral Treatment of A375 Melanoma Xenografts (at least 10 mm in Size).

| Treatment | N | 12.5 to 14 mm Tumors<br>Volume Range | Avg Volume | Regressions            |   |   | Total Number of<br>Regressions <sup>a</sup> | % Regressions <sup>c</sup> |
|-----------|---|--------------------------------------|------------|------------------------|---|---|---|----------------------------|
|           |   |                                      |            | Complete<br>Regression | Partial <sup>a</sup><br>>25% and 50% <sup>b</sup> |   |   |                            |
| 3.0E+08   | 3 | 632 to 787                           | 698        | 1                      | 1   | 0 | 2   | 67                         |
| 3.0E+08   | 2 | 717 to 860                           | 788        | 0                      | 0   | 0 | 0   | 0                          |
|           |   |                                      |            |                        |   |   |   |                            |
|           |   | 10 to 12 mm Tumors<br>Volume Range   |            |                        |   |   |   |                            |
| 3.0E+08   | 8 | 320 to 600                           | 411        | 0                      | 3   | 4 | 7   | 088 <sup>d</sup>           |
| 3.0E+06   | 8 | 425 to 662                           | 502        | 0                      | 0   | 2 | 2   | 025                        |
| 3.0E+05   | 8 | 245 to 600                           | 421        | 0                      | 0   | 1 | 1   | 013                        |
| 3.0E+04   | 8 | 336 to 600                           | 477        | 0                      | 0   | 1 | 1   | 013                        |
| 3.0E+03   | 8 | 281 to 542                           | 349        | 2                      | 0   | 0 | 2   | 25                         |
| 3.0E+02   | 8 | 281 to 662                           | 372        | 0                      | 0   | 0 | 0   | 0                          |
| Saline    | 8 | 379 to 666                           | 518        | 0                      | 0   | 0 | 0   | 0                          |

<sup>a</sup> - Partial regression is defined as regression less 100% and equal to or greater than 50%.

<sup>b</sup> - "Regression ">25% and <50%" is defined as tumor regression greater than 25% and less than 50%.

<sup>c</sup> - Includes all tumor regressions that are at least 25%

<sup>d</sup> - P < 0.0001 for regression greater than 25% in the 3E+08 group versus the saline group.

**Example 7****Fourth Experiment Using PPMK107 for Intratumoral Treatment of Large A375 Melanoma Xenografts in Athymic Mice.**

5 Tumors of largest dimension 10 to 12 mm were established as in Example 4 thirteen days after tumor cell inoculation. Intratumoral treatment consisted of a single injection of  $3 \times 10^8$  PFU of PPMK107 or saline. Volumes of those tumors treated with PPMK107 ranged from 295 to 600 mm<sup>3</sup> (average tumor volume of 437 mm<sup>3</sup>). Groups of mice in each treatment group were euthanized on days 0, 2, 3, 4, 7, and 14 for tumor histology. For those mice  
10 observed for a minimum of 4 days, eleven out of 12 mice treated with PPMK107 exhibited regression of at least 25% compared to none of 8 in the saline group ( $P < 0.0001$ , Table 12). At 2 days after PPMK107 treatment, two tumors already exhibited signs of regression but the degree of regression was less than 25%.

**Example 8****Fifth Experiment Using PPMK107 for Intratumoral Treatment of Large A375 Melanoma Xenografts in Athymic Mice.**

15 Tumors of largest dimension 10 to 12 mm were established as in Example 4 twenty days after tumor cell inoculation. Intratumoral treatment consisted of a single injection of  $3 \times 10^8$  PFU of PPMK107 or saline. Volumes of those tumors treated with PPMK107 ranged from  
20 361 to 756 mm<sup>3</sup> (average tumor volume of 551 mm<sup>3</sup>). Nine out of 10 mice treated with PPMK107 exhibited a regression of at least 25% compared to none of 10 in the saline group ( $P < 0.0001$ , Table 13).

**Example 9****First Experiment Using PPMK107 for Intravenous Treatment of Large HT1080 Fibrosarcoma Xenografts.**

25 Athymic mice were injected subcutaneously with 10 million HT1080 human fibrosarcoma cells. Six days later, tumors were treated with a single injection PPMK107 (at a dose of  $1.5 \times 10^9$  PFU) or saline. For those tumors 10 to 11 mm in single largest  
30 dimension, five out of six tumors completely or partially regressed in response to a single intravenous injection of PPMK107 compared to none of the saline treated tumors (Table 14,  $P < 0.025$ ). These results indicate that tumors at least 1 cm in length are sensitive to intravenous PPMK107 treatment.

Table 12. Fourth Experiment Using PPMK107 for the Intratumoral Treatment of A375 Melanoma Xenografts (at least 10 mm in Size)

| Treatment | Day Euthanized<br>Post Treatment | N  | Regressions            |                      |                           | Total Number of<br>Regressions <sup>e</sup> | % Regressions <sup>c</sup> |
|-----------|----------------------------------|----|------------------------|----------------------|---------------------------|---|----------------------------|
|           |                                  |    | Complete<br>Regression | Partial <sup>a</sup> | >25% and 50% <sup>b</sup> |   |                            |
| 3.0E+08   | 14 days                          | 3  | 0                      | 2                    | 1                         | 3   | 100                        |
| 3.0E+08   | 7 days                           | 3  | 0                      | 2                    | 1                         | 3   | 100                        |
| 3.0E+08   | 4 days                           | 3  | 0                      | 2                    | 1                         | 3   | 100                        |
| 3.0E+08   | 3 days                           | 3  | 0                      | 0                    | 2                         | 3   | 67                         |
| 3.0E+08   | All PPMK107 Groups               | 12 | 0                      | 6                    | 5                         | 11  | 92 <sup>d,e</sup>          |
| Saline    | 14 days                          | 2  | 0                      | 0                    | 0                         | 0   | 0                          |
| Saline    | 7 days                           | 2  | 0                      | 0                    | 0                         | 0   | 0                          |
| Saline    | 4 days                           | 2  | 0                      | 0                    | 0                         | 0   | 0                          |
| Saline    | 3 days                           | 2  | 0                      | 0                    | 0                         | 0   | 0                          |
| Saline    | All Saline Groups                | 8  | 0                      | 0                    | 0                         | 0   | 0                          |

<sup>a</sup> - Partial regression is defined as regression less 100% and equal to or greater than 50%.

<sup>b</sup> - "Regression ">25% and <50%" is defined as tumor regression greater than 25% and less than 50%.

<sup>c</sup> - Includes all tumor regressions that are at least 25%

<sup>d</sup> - P < 0.03 for Complete or Partial Regression in the PPMK107 group of 12 mice versus the saline group of 8 mice.

<sup>e</sup> - P < 0.0001 for all tumor regression at least 25% in the PPMK107 group of 12 mice versus the saline group of 8 mice.

**Table 13. Fifth Experiment Using PPMK107 for the Intratumoral Treatment of A375 Melanoma Xenografts (at least 10 mm in Size)**

| Treatment | N  | Regressions         |                      |                           | Total Number of Regressions <sup>c</sup> | % Regressions <sup>c</sup> |     |
|-----------|----|---------------------|----------------------|---------------------------|--|----------------------------|-----|
|           |    | Complete Regression | Partial <sup>a</sup> | >25% and 50% <sup>b</sup> |  |                            |     |
| 3.0E+08   | 10 | 0                   | 4                    | 5                         | 9  | 90                         | d,e |
| Saline    | 10 | 0                   | 0                    | 0                         | 0  | 0                          |     |

<sup>a</sup> - Partial regression is defined as regression less 100% and equal to or greater than 50%.

<sup>b</sup> - "Regression ">25% and <50%" is defined as tumor regression greater than 25% and less than 50%.

<sup>c</sup> - Includes all tumor regressions that are at least 25%

<sup>d</sup> -  $p < 0.05$  for Complete or Partial Regression in the PPMK107 group versus the saline group.

<sup>e</sup> -  $p < 0.0001$  for all tumor regression at least 25% in the PPMK107 group versus the saline group.

**Table 14. Intravenous Treatment of Subcutaneous HT1080 Human Fibrosarcoma Xenografts in Athymic Mice. Tumor Size = 10-11 mm.**

| Treatment | Dose    | N | Complete Regression | %               | Complete + Partial Regression | %               |
|-----------|---------|---|---------------------|-----------------|-------------------------------|-----------------|
| PPMK107   | 1.5E+09 | 6 | 4                   | 67 <sup>a</sup> | 5                             | 83 <sup>a</sup> |
| Saline    |         | 4 | 0                   | 0               | 0                             | 0               |

<sup>a</sup> P < 0.025 (by Fisher's exact test) for complete or partial regression (at least 50% regression) in the PPMK107 treated group compared to saline group.

5

### **Example 10**

#### **Specific Clearing of PPMK107 Infection from Normal but Not Tumor Cells.**

In order to examine the mechanism of tumor-specific killing by NDV strain PPMK107, representative tumor cells were chosen based on the following criteria: a) ability to form tumors as xenografts in athymic mice; b) the tumor xenografts are specifically killed in vivo following administration of PPMK107; c) the tumors cells exhibit killing by PPMK107 in vitro at virus concentrations that are several logs below the concentration to kill resistant, normal cells; and d) tumor cells must be easily distinguished from the normal cells when present as a co-culture.

Xenograft tumors comprised of KB head and neck carcinoma cells exhibit 83% complete or partial regression in response to a single intratumoral injection of PPMK107, are more than four logs more sensitive to killing by PPMK107 in vitro than are normal primary skin fibroblasts (CCD922-sk), and are easily distinguished from CCD922-sk cells when present as a co-culture.

Accordingly, co-cultures of KB and CCD922-sk cells were infected at a multiplicity of infection (m.o.i., the ratio of virus added per cell) of 0.0005 and the course of the infection followed for 5 days by immunohistochemical staining for a viral antigen (NDV P protein). Infection of normal cells peaked at 2 days with little or no apparent cell death as determined by visual inspection of the cell monolayer. On the third day post-infection the amount of viral expression in the normal cells decreased significantly, while infection of the tumor cells was clearly apparent. The amount of viral antigen virtually disappeared in the normal cells on days 4 and 5, while the infection in the tumor cells progressed rapidly through the tumor cell population resulting in destruction of the majority of the tumor cells present in the co-culture.

Thus, normal cells were infected and easily cleared the infection in a manner consistent with the anti-viral effects of IFN. The tumor cells were unable to establish an anti-viral state in response and were killed by the unabated viral growth, despite the presence of physiologically effective concentrations of IFN secreted into the media by the normal cells.

5

### **Example 11**

#### **Demonstration that Interferon is an Important Component of Viral Clearing in Normal CCD922-sk Cells.**

The hypothesis that interferon was mediating the ability of CCD922-sk cells to clear the infection of PPMK107 was tested. Polyclonal neutralizing antibodies to human interferon- $\alpha$  or human interferon- $\beta$ , used alone or in combination, were added daily to cultures of CCD922-sk cells infected with PPMK107 at an moi of 0.0005 and the progress of the infection followed for three days. The amount of viral antigen present in the cells increased in proportion to the concentration of neutralizing antibody, with the effect of the anti-interferon- $\beta$  antibody being more marked than that of the anti-interferon- $\alpha$  antibody; consistent with reports that fibroblasts produce predominantly the beta form of interferon.

15

The ability to make the normally insensitive cells more susceptible to infection with PPMK107 through the addition of neutralizing antibody to interferon supports the hypothesis that a key difference between the sensitivity of normal and tumor cells to killing by PPMK107 lies in the ability of normal cells, but not tumor cells, to establish an interferon-mediated anti-viral response.

20

### **Example 12**

#### **Demonstration that Interferon- $\beta$ is an Important Component of Viral Clearing in Other Normal Cells.**

25

In this experiment, it was determined that another normal cell (NHEK, normal human epithelial cells) known to be quite resistant to killing by PPMK107, was made more sensitive through the addition of polyclonal anti-interferon- $\beta$  antibody to a culture of infected cells. NHEK (normal human epithelial keratinocyte) cells were infected at an moi of either 0.0005 or 0.05 and had antibody added daily over five days.

30

In the cultures infected at the low moi (0.0005), antibody dependent augmentation of viral antigen expression was clear at five days post-infection, but was less clear earlier in the experiment. Antibody addition to cultures infected with PPMK107 at an moi of 0.05 resulted

in a marked increase in viral antigen at 4 and 5 days post-infection. At 2 and 3 days post-infection the addition of neutralizing antibody resulted in less accumulation of viral antigen (Fig. 1).

The culture supernatants from the high moi samples were also titrated for the amount of infectious virus present by plaque assay on human HT1080 fibrosarcoma tumor cells; the standard assay system in our laboratory. Results from this analysis demonstrated that at five days post-infection there was 19-fold increase in the amount of infectious virus in the antibody-treated cultures relative to mock-treated controls (Fig. 1).

These results suggest a general mechanism by which normal cells are protected from killing by PPMK107 through an interferon-related mechanism.

### **Example 13**

#### **Comparison of the Effect of Interferon- $\beta$ on PPMK107 Infection in Tumor and Normal Cells.**

A comparison of the effect of exogenously added interferon- $\beta$  on the infection of normal (CCD922-sk) and tumor cells of high (KB) or intermediate (HEp2) sensitivity PPMK107 was performed. Separate cultures of the three cells were treated with interferon- $\beta$  at 20, 200, or 2000 units/ml 1 day pre- and 2 days post-infection at an moi of 0.0005.

At 3 days post-infection the low level of viral antigen expression present in the normal cells was eliminated at all doses of interferon used. Conversely, the addition of interferon to the highly sensitive KB tumor cells at concentrations of 2 or 200 units/ml decreased relative levels of viral antigen expression 2-fold, with complete suppression at 1000 units/ml interferon. The intermediately sensitive HEp-2 cells responded to the exogenous interferon by clearing viral antigen expression at all of the interferon doses used (Fig. 2).

The pattern of sensitivity in the KB and CCD922-sk cells to the anti-viral effects of exogenously added interferon- $\beta$  was inversely proportional to the sensitivity of these cells to killing by PPMK107. The ability of the HEp-2 cells to respond to the effects of interferon indicates that these cells are able to efficiently utilize the concentrations of interferon used in this experiment. Similarly, the response of the KB cells to the high doses of interferon suggests that the inability to establish an interferon-mediated anti-viral response does not result from an absolute defect in the interferon pathway, but rather a relative insensitivity compared to normal cells.



**Example 14****Effect of Low Concentrations of Interferon- $\beta$  on the Infection of Normal and Tumor Cells by PPMK107.**

In this experiment normal (CCD922-sk) and tumor (KB) cells were treated with low concentrations of interferon- $\beta$  (0.2, 2, and 20 units/ml) 1 day before and 2 days post-infection with PPMK107 at an moi of 0.05.

Under these conditions the normal cells experienced a dose-dependent decrease in the amount of viral antigen, while the relative levels of viral antigen in the tumor cells was unaffected by the addition of exogenous interferon (Fig. 3).

**Example 15****PPMK107 Purification****Method A**

PPMK107 was derived from the mesogenic Newcastle disease virus strain Mass-MK107 by triple plaque purification. Approximately 1000 PFUs (plaque forming units) of live PPMK107 were inoculated into the allantoic fluid cavity of each 10 day old embryonated chicken egg. After incubation at 36<sup>0</sup>C for 46 hours, the eggs were chilled and then the allantoic fluid was harvested. Cells and cell debris were removed from the allantoic fluid by centrifugation at 1750 x g for 30 minutes. The clarified allantoic fluid (supernatant containing virus) was then layered over a 20%/55% discontinuous sucrose gradient) and centrifuged at approximately 100,000 x g for 30 minutes. The purified virus was harvested from the 20%/55% interface and dialyzed against saline to remove the sucrose.

**Method B**

In another advantageous embodiment, the clarified allantoic fluid was frozen at -70<sup>0</sup>C. After thawing, the fluid was maintained at 1 to 4<sup>0</sup>C overnight and then the contaminating material was removed from the virus suspension by means of centrifugation (1750 x g for 30 minutes). This material was further processed using the discontinuous sucrose gradient on the ultracentrifuge as above.

### Method C

In another advantageous embodiment, ultracentrifugation on the discontinuous sucrose gradient was accomplished by means of a continuous flow ultracentrifuge.

### Method D

In another advantageous embodiment, harvested allantoic fluid is diluted with a buffer containing 5% mannitol and 1.0% l-lysine, pH 8.0 (ML buffer) and is clarified and exchanged with ML buffer by tangential flow filtration (TFF) through filters with a nominal pore size of 0.45 $\mu$ . The permeate containing the clarified virus in ML buffer is collected and virus is purified by TFF through filters with a nominal cut-off of 300,000 daltons in ML buffer. The concentrated, purified virus in ML buffer is collected as the retentate from this step and is again diluted with ML buffer before being applied to a Sephacryl S500 (Pharmacia) gel permeation column equilibrated with ML buffer. Fractions containing purified virus are collected, pooled and can be reconcentrated by TFF through filters with a nominal cut-off of 300,000 daltons with ML buffer.

## Results

### \* Clonal Virus

After generation of PPMK107 by plaque purification, eight individual molecular clones from the population of virions were found to have an identical sequence (e.g, a homology of 100%) of over 300 contiguous nucleotides within the fusion protein gene of NDV. PPMK107 is a clonal virus with a high degree of genetic homogeneity.

### \* PFU/mg protein

One quantitative means of measuring purity is by determination of a PFU/mg protein. The activity of the virus preparations was determined by the plaque assay method using HT1080 and the protein content of the virus preparations was determined using the Modified Lowrey Assay (Bio-Rad, Hercules, CA) with bovine serum as the protein standards. Higher values indicate a greater level of purity. Using Method A, PFU/mg values of at least  $4.8 \times 10^{10}$  were achieved (see Table 15). Using Method C, PFU/mg protein values of at least  $2.0 \times 10^{10}$  were achieved. For a mesogenic strain of NDV, a literature value for this measurement

of purity has not been found. The best estimate for a mesogenic strain of NDV is the virus preparation (NDV MassMK107, lot RU2, prepared as in Faaberg KS and Peeples, ME, 1988, J Virol 62:586; and Bratt, MA and Rubin, H. 1967, Virology 33:598-608). This RU2 lot was found to have a PFU/mg of  $1.3 \times 10^9$  PFU/mg of protein. The purity values achieved by Method A are approximately 40 times better than what the Peeples method achieved (see Table 15).

#### \* Particle per PFU Ratio

Another quantitative means of measuring purity is by determination of a ratio of particles per PFU. Lower values indicate a greater level of purity. Particle counts were done by electron microscopy using standard methods. Using either Method A or Method B, particles per PFU values near one were achieved (Table 15).

**Table 15. Virus Purity**

| <u>Virus Preparation Method</u> | <u>Virus</u> | <u>Lot #</u> | <u>PFU per<br/>mg protein</u> | <u>Particle<br/>per PFU</u> |
|---------------------------------|--------------|--------------|-------------------------------|-----------------------------|
| Preferred Method A              | PPMK107      | L2           | $4.8 \times 10^{10}$          | 0.80                        |
|                                 |              | L4           | $6.9 \times 10^{10}$          | NT <sup>a</sup>             |
|                                 |              | L5           | $6.6 \times 10^{10}$          | NT                          |
|                                 |              | L6           | $7.7 \times 10^{10}$          | 0.55                        |
|                                 |              | L7           | $6.1 \times 10^{10}$          | NT                          |
| Preferred Method C              | PPMK107      | D004         | $2.0 \times 10^{10}$          | 0.32                        |
|                                 |              | D005         | $4.5 \times 10^{10}$          | 0.52                        |
|                                 |              | D010         | $4.4 \times 10^{10}$          | NT                          |
| Preferred Method D              | PPMK107      | RD2          | $5.6 \times 10^{10}$          | NT                          |
|                                 |              | RD3          | $5.0 \times 10^{10}$          | NT                          |

<sup>a</sup> NT. Not Tested

Virus preparations using Methods A and C also permitted purification of NDV to a level substantially free of contaminating egg proteins. For the PPMK107 lot 7 preparation using Method A ovalbumin, was not detectable in a Western blot using (1)  $1.7 \times 10^9$  PFU of purified virus per well (3.3 cm in width) run on an SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) gel (1 mm thick); (2) a nitrocellulose membrane for transfer; and (3) rabbit anti-ovalbumin (Cappel rabbit IgG fraction at a 1:200 dilution of a 4 mg/ml antibody concentration). For PPMK107 preparations using Method D and analyzed by SDS-PAGE followed by silver staining, no band corresponding to ovalbumin was observed.

### Example 16

#### **PPMK107 Treatment of Ascites-Forming ES-2 Ovarian Carcinoma in Athymic Mice.**

In this experiment, all of the athymic mice (female, NCR nu/nu, 8 weeks old) were given an intraperitoneal injection of  $10^6$  ES-2 cells. Seven days later before ascites had developed, they were treated intraperitoneally with saline or PPMK107 (at  $1 \times 10^9$  PFU). As shown in Figure 4, there was a markedly improved survival in the animals treated with PPMK107 compared to saline. The majority of the mice in the saline treated group had developed ascites by seven days post-treatment and by day 38, all of these animals had died. In marked contrast, 92% of the mice treated with PPMK107 were still alive by day 38 and 25% of these animals were long term survivors (>120 day survival).

### Example 17

#### **PPMK107 Treatment of ES-2 Ovarian Carcinoma in Athymic Mice When Ascites is Present.**

In this experiment, all of the athymic mice (female, NCR nu/nu, 8 weeks old) were given an intraperitoneal injection of  $10^6$  ES-2 cells. Fourteen days later when the majority of mice had developed ascites, the mice without ascites were excluded and the mice with ascites were randomized into 7 intraperitoneal treatment groups (PPMK107- one treatment on day 0; PPMK107- two treatments for the first week; PPMK107- one treatment per week; PPMK107- two treatments per week; saline- one treatment on day 0; saline-two treatments for the first week; saline-two treatments per week). A dose of  $1 \times 10^9$  PFU/mouse was used for each virus treatment. All of the mice before the first treatment and any additional treatments were drained of the ascites fluid.

The degree of ascites was quantified and noted as follows:

| Ascites Score | Degree of Ascites  |
|---------------|--|
| 1.0           | Animal appears normal- little or no ascites present                      |
| 2.0           | Abdomen slightly distended; animal is capable of normal functions        |
| 3.0           | Abdomen distended; animal is slow-moving, hunched with a staggered gait. |
| 4.0           | Abdomen completely distended; animal moribund                            |
| 5.0           | Death after ascites development  |

As shown in Table 16, all of the saline-treated animals had more advanced ascites than the PPMK107-treated animals on both days 7 and 10. On day 7 post initial treatment, each the saline group had ascites scores above 3.5 while all of the PPMK107-treated animals had ascites scores at 3.0 or below. Similarly on day 10 post initial treatment, each the saline group had ascites scores above 4.5 while all of the PPMK107-treated animals had ascites scores at 4.1 or below. These results indicate that ascites fluid production was markedly decreased in virus-treated animals compared to saline controls.

**Table 16. PPMK107 Treatment of ES-2 Ovarian Carcinoma in Athymic Mice When Ascites is Present.**

| Treatment         | # of Mice | Ascites Score, Day 7 | Ascites Score, Day 10 |
|-------------------|-----------|----------------------|-----------------------|
| Saline x1         | 12        | 4.3                  | 4.7                   |
| Saline x2         | 12        | 3.7                  | 4.6                   |
| Saline x2 per wk  | 12        | 4.3                  | 4.8                   |
| PPMK107 x 1       | 17        | 3.0                  | 4.1                   |
| PPMK107 x 2       | 17        | 2.3                  | 3.6                   |
| PPMK107 x1 per wk | 17        | 2.6                  | 2.6                   |
| PPMK107 x2 per wk | 17        | 2.2                  | 3.6                   |

**Example 18****Use of a Desensitizing Dose of PPMK107 to Reduce the Lethality of a Subsequent Dose of PPMK107.**

5 C57BL/6 mice (seven weeks old) were injected intravenously on day 0 with either saline or a desensitizing dose of PPMK107 ( $3 \times 10^8$  PFU/mouse). Two days later each set of mice were further subdivided into groups for intravenous dosing with saline or PPMK107 (at doses of  $1 \times 10^9$ ,  $2.5 \times 10^9$ ,  $5 \times 10^9$ , and  $1 \times 10^{10}$  PFU/mouse). As shown in Table 16 below, when saline was used to pretreat the mice, deaths were recorded in the mice subsequently dosed with  $2.5 \times 10^9$ ,  $5 \times 10^9$ , and  $1 \times 10^{10}$  PFU. The doses of  $5 \times 10^9$  and  $1 \times 10^{10}$  PFU were 100% lethal to the mice pretreated with saline. In contrast, no deaths were seen in any group of mice given a desensitizing dose of PPMK107 on day 0 followed by PPMK107 injection two days later at dose levels up to  $1 \times 10^{10}$  PFU. These data indicate that PPMK107 can be used to desensitize the lethality of subsequent dosing with this same agent. Furthermore, the maximal tolerated dose of PPMK107 can be raised by an approximate order of magnitude when using this virus as a desensitizing agent.

**Table 17. Use of a Desensitizing Dose of PPMK107 to Reduce the Lethality of a Subsequent Dose of PPMK107.**

| Group | Injection on Day 0 | Dose on Day 2      | # of Mice | # of Deaths | % Lethality |
|-------|--------------------|--------------------|-----------|-------------|-------------|
| 1     | Saline             | Saline             | 8         | 0           | 0           |
| 2     | Saline             | PPMK107, $1.0E+09$ | 8         | 0           | 0           |
| 3     | Saline             | PPMK107, $2.5E+09$ | 8         | 3           | 38          |
| 4     | Saline             | PPMK107, $5.0E+09$ | 8         | 8           | 100         |
| 5     | Saline             | PPMK107, $1.0E+10$ | 8         | 8           | 100         |
| 6     | PPMK107, $3E+08$   | Saline             | 8         | 0           | 0           |
| 7     | PPMK107, $3E+08$   | PPMK107, $1.0E+09$ | 8         | 0           | 0           |
| 8     | PPMK107, $3E+08$   | PPMK107, $2.5E+09$ | 8         | 0           | 0           |
| 9     | PPMK107, $3E+08$   | PPMK107, $5.0E+09$ | 8         | 0           | 0           |
| 10    | PPMK107, $3E+08$   | PPMK107, $1.0E+10$ | 8         | 0           | 0           |

**Example 19****Slower Intravenous Injection Rate Reduces the Toxicity of PPMK107.**

Twenty two athymic mice (8 weeks old) were anesthetized with a combination of ketamine/xylazine and placed into a restrainer to help inhibit their movement during the injection process to allow for either a slow or rapid injection of PPMK107. For the slow injection group, 0.2 mL of  $4 \times 10^9$  PFU of PPMK107 in saline was injected intravenously over a 4 minute period with 0.01 mL given every 10 to 15 seconds. The rapid injection group received the same dose and volume but over a 30 second period. As shown in Table 18, the animals receiving their dose of PPMK107 over 4 minutes had half as much maximal weight loss (recorded on day 2 after dosing) as the animals receiving the same IV dose over 30 seconds. These results indicate that PPMK107 has less toxicity and is safer for intravenous administration when injected at such slower rates.

**Table 18. Slower IV Injection of PPMK107 Results in Reduced Toxicity.**

| Group                      | Length of Time That Dose was Administered | # of Mice | Maximal Percent Weight Loss |
|----------------------------|---|-----------|-----------------------------|
| Rapid Injection of $4E+09$ | 30 seconds                                | 11        | 12%                         |
| Slow Injection of $4E+09$  | 4 minutes                                 | 11        | 6%                          |

**Example 20****Use of PPMK107 in the Treatment of Patients with Advanced Cancer.**

PPMK107 is currently being tested in a phase I clinical trial in the U.S.A. by the intravenous route. To date, a total of 52 patients with advanced solid tumors, no longer amenable to established therapies, have been treated with PPMK107. Seventeen of these patients have received a single dose for the initial treatment course. Thirteen other patients have received three of the same doses per week for one week for the initial treatment course. Twenty-two more patients have received three doses per week for one week for the initial treatment course with the first dose a desensitizing dose of  $12 \text{ billion PFU/m}^2$  and the two subsequent higher doses of between 24 to 96 billion  $\text{PFU/m}^2$ . The sizes of each patient's tumors were followed once per month. Patients with at least stable disease (less than 25%

increase and less than 50% decrease in the sum of the products of all measurable tumors in the absence of any new lesions) were eligible for additional treatment courses each month.

### **Regressions of Individual Tumors in Cancer Patients:**

Regressions of individual tumors were observed in 5 patients (one in the single dose regimen, one patient in the repeat same dose regimen and three patients in the desensitizing dose regimen; Table 19). A higher rate of tumor regression (16% of patients) was noted in those receiving higher second and third doses as part of the desensitizing regimen than when patients received three of the same doses in the repeat same dose regimen (8% tumor regression).

**Table 19. Regression of Individual Tumors in Patients with Advanced Cancer using PPMK107.**

| Regimen   | # of Patients Treated at this Dose Level | # of Patients with Tumor Regressions | % of Patients with Tumor Regression | Types of Cancer with Tumor Regression    |
|---|--|--------------------------------------|-------------------------------------|--|
| Single Dose                                     | 17                                       | 1 of 17                              | 6%                                  | Colon Cancer                             |
| Repeat Same Dose                                | 13                                       | 1 of 13                              | 8%                                  | Breast Cancer                            |
| Desensitizing Dose followed by Two Higher Doses | 22 (19 evaluated)                        | 3 of 19                              | 16%                                 | Mesothelioma<br>Melanoma<br>Colon Cancer |
| Total   | 52 (49 evaluated)                        | 5 of 49                              | 10%                                 | As noted above                           |

These cases are summarized below:

#### **(A) Tumor Regression of a Palpable Colon Metastasis**

A 68 year old woman with colon carcinoma had a palpable abdominal tumor among her widespread metastases. After a single IV treatment with PPMK107 at 12 billion PFU/m<sup>2</sup>, this patient experienced a 91% regression of this single abdominal wall tumor over the course



of two weeks (Table 20 below). Measurements of the tumor one day after dosing (3.75 x 3 cm) were similar to the baseline measurements of 4 x 3 cm. However, by day 7 post dosing, the tumor had decreased in size to 2 x 2 cm and continued to decrease in size to 1.5 x 1.5 cm by day 14 after PPMK107 dosing. Previous to PPMK107 treatment, this tumor mass had been rapidly growing with a 1065% increase in tumor volume in the two weeks before PPMK107 dosing. This patient was taken off study because of increased growth of the tumor elsewhere.

**Table 20. Size of Palpable Abdominal Wall Tumor in Patient #123 (68 year old Female with Metastatic Colon Carcinoma) After a Single IV PPMK107 Dose of 12 Billion PFU/m<sup>2</sup>.**

| Date    | Time After Dosing | Tumor Dimensions (L x W, cm <sup>3</sup> ) | Tumor Volume (0.5 x L x W x W, cm <sup>3</sup> ) | % Reduction in Tumor Volume |
|---------|-------------------|--|--|-----------------------------|
| 7/23/98 | Day 0             | 4 x 3                                      | 18.  | -                           |
| 7/24/98 | Day 1             | 3.75 x 3                                   | 16.9   | 6%                          |
| 7/30/98 | Day 7             | 2 x 2                                      | 4.0  | 78%                         |
| 8/6/98  | Day 14            | 1.5 x 1.5                                  | 1.7  | 91%                         |

#### **B) Regression of a Chest Wall Tumor in a Woman with Breast Cancer**

A 58 year old woman with breast carcinoma had a palpable chest wall mass apparent to visual inspection. During her second course of PPMK107 treatment with three doses of 5.9 billion PFU/m<sup>2</sup>, her chest wall tumor mass by visual and palpable inspection decreased ~90%. This patient was taken off study after her third course of therapy because of increased growth of the cancer elsewhere.

#### **C) Regression of Abdominal Tumors in a Patient with Peritoneal Mesothelioma**

A 46 year old man with peritoneal mesothelioma had three large (8 to 10 cm) masses regress 50%, 42% and 10%, respectively, after his first course of PPMK107 treatment consisting of a desensitizing dose of 12 billion PFU/m<sup>2</sup> followed by two doses at 48 billion PFU/m<sup>2</sup>. His other remaining large tumor mass (9.8 cm in size) remained stable after this

first course of treatment. This patient is currently still on study. His most recent CT scan still indicated significant tumor regression of at least 30 to 36% from baseline for two of his metastases and overall disease stabilization.

5      **D) Regression of Metastatic Tumors in a Patient with Melanoma.**

A 57 year old man with melanoma had two tumor masses completely regress after his first course of PPMK107 treatment consisting of a desensitizing dose of 12 billion PFU/m<sup>2</sup> followed by two doses at 48 billion PFU/m<sup>2</sup>. The two tumors which disappeared after PPMK107 treatment were a palpable groin mass of 1 cm in size and a small lung metastasis. This patient was taken off study because of increased growth of the tumor elsewhere.

10      **E) Continued Regression of a Liver Metastasis in a Patient with Colon Cancer.**

A liver metastasis in the caudate lobe of a 79 year old man with colon carcinoma regressed 59% after his first course of PPMK107 and regressed 97% after his second course. Treatment consisting of a desensitizing dose of 12 billion PFU/m<sup>2</sup> followed by two doses at 72 billion PFU/m<sup>2</sup>. At baseline before treatment, this tumor measured 3 x 3 cm (tumor volume of 13.5 cm<sup>3</sup> based on a  $\frac{1}{2} \times L \times W^2$  formula). After his first course of PPMK107, it decreased 59% to 2.8 x 2 cm (tumor volume of 5.6 cm<sup>3</sup>). Three weeks after his second course of PPMK107, this same tumor mass in the caudate lobe was reported as measuring 3 x 0.5 cm (tumor volume of 0.38 cm<sup>3</sup>), a 97% decrease from baseline.

20      **Stabilization of Cancer**

Twenty one other patients, all of whom previously had tumor progression with conventional cancer therapies, have experienced benefit in the form of stabilization of their advanced cancer after PPMK107 dosing. These patients with stable disease represent those with diverse types of cancer including renal cancer, pancreatic cancer, breast cancer, bladder cancer, cholangiocarcinoma of the gallbladder, and lung cancer. Included among these cases are the following: (1) seven month stable disease in a patient with renal cancer; (2) seven month stable disease in a patient with lung cancer; (3) five month stable disease in a patient with pancreatic cancer; (4) five month stable disease in another patient with pancreatic cancer; (5) ongoing 3 month stable disease in a patient with renal cancer; (6) ongoing 2 month stable disease in a patient with cholangiocarcinoma of the gallbladder.

### Reduction in Pain Medication

One patient at the single dose 5.9 billion PFU/m<sup>2</sup> dose level has benefited from PPMK107 treatment in the form of symptomatic relief of cancer pain as denoted by a reduction in narcotic pain medication.

### Desensitization

In the desensitizing regimen, a clear desensitizing effect from the first dose (at 12 billion PFU/m<sup>2</sup>) is seen on subsequent doses within that same week. In general, the reported side effects from second and third doses have been of lower incidence and milder, even when these doses are 2 to 8 times higher (at between 24 to 96 billion PFU/m<sup>2</sup>) than the first dose. For example, while fever has been reported in 68% of patients (including 9% with a grade 3 fever spike) after the first dose, it was only reported in 32% of patients (none with grade 3 fever) after the second dose and was reported in only 5% of patients after the third dose. As another example, chills were seen in 50% of the patients after the first dose, 18% of the patients after the second dose, and in only 14% of the patients after the third dose.

As another example, in the repeat same dose study, the first 4 patients in this multidose treatment regimen (three doses of 5.9 billion PFU/m<sup>2</sup> per week for one week) had fever after the first dose in spite of receiving prophylactic antipyretic treatment with acetaminophen and ibuprofen. The majority of these patients had no fever after receiving the second and third doses, even in cases in which they did not receive antipyretics. There is therefore strong evidence that administration of the first dose in the three times per week schedule reduces the toxicity for the second and third doses.

### Dosing Through Neutralizing Antibodies in Serum

Using the dose range in this phase I study ( $\geq 5.9$  billion PFU/m<sup>2</sup>), there is also clear indication that one can effectively deliver virus to patients even if they have generated neutralizing antibodies. A 72 year old woman with pancreatic cancer at the 12 billion PFU/m<sup>2</sup> single dose level has had stable disease for 2 months since beginning PPMK107 treatment. A second course (consisting of a single IV dose of PPMK107) was administered one month after the first dose when the patient had produced neutralizing antibodies in her serum. Seven days after this second course, her urine was positive for PPMK107 at a titer of at least 40 PFU per mL.

Additional evidence indicating that antitumor efficacy is achievable using the dose ranges in this trial ( $\geq 5.9$  billion PFU/m<sup>2</sup>) in spite of the presence of neutralizing antibody is taken from a 58 year old woman with breast cancer that had spread to her chest wall. As noted in the section discussing tumor regression, her chest wall tumor mass regressed ~90% during her second course of therapy. This effect occurred between weeks 5 to 6 after her initial course, at a time in which her antibody had a titer of 1:256 (at the beginning of week 5) and rose to >1:2560 (by the beginning of week 6). Further evidence that virus can be delivered effectively to this patient in spite of the presence of neutralizing antibody is indicated by the positive urine sample (20 to 40 PFU/ml) seen at the end of week 5 (when her baseline urine at the beginning of week 5 had been negative).

These results indicate that the neutralizing antibodies to PPMK107 in these patients' serum was not able to completely inhibit the virus nor the virus's antitumor efficacy with a second treatment course.

#### Example 21

##### **Summary of Cytotoxicity Assay Results with Newcastle Disease Virus PPNJROAKIN**

Human tumor cells and normal cells were grown to approximately 80% confluence in 24 well tissue culture dishes. Growth medium was removed and PPNJROAKIN, a plaque purified clone of the mesogenic Newcastle disease virus strain New Jersey Roakin-1946, was added in 10 fold dilutions ranging from  $10^7$  plaque forming units (PFU)/well to 1 PFU/well. Controls wells with no virus added were included on each plate. Virus was adsorbed for 90 minutes on a rocking platform at 37°C. At the end of the incubation period, the viral dilutions were removed and replaced by 1 ml of growth medium. Plates were then incubated for 5 days at 37°C in 5% CO<sub>2</sub>. Cytotoxicity was quantified by using a colorimetric MTT (2-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Cell Titer 96, catalog #G4000, Promega Corporation, Madison WI 53711) monitored at 570 nm, that detects mitochondrial enzyme activity (Mosman, T., 1983, J. Immunol. Methods 65:55). The viability in the virus treated wells was expressed as a percent of the activity in untreated control wells. The data was plotted graphically as PFU/well vs. viability as a percent of control. The IC<sub>50</sub> was calculated as the amount of virus in PFU/well causing a 50% reduction in the amount of viable cells.

**Table 21. Summary of Cytotoxicity Assay Results with PPNJROAKIN.**

| <u>Cell Type</u>           | <u>Cell Line</u> | <u>IC<sub>50</sub> (PFU/well)</u> |
|----------------------------|------------------|-----------------------------------|
| Fibrosarcoma               | HT1080           | 13.8                              |
| Head and Neck<br>Carcinoma | KB               | 2.4                               |
| Normal Fibroblast          | CCD922sk         | 1.2 x 10 <sup>4</sup>             |

5           These results show that PPNJROAKIN demonstrates tumor-selective killing of at least two different human tumor cells (HT1080 and KB) relative to normal skin fibroblasts. The IC<sub>50</sub> values for the two tumor cell lines are between 800 and 5000-fold lower than that for normal cells.

#### **Example 22**

##### **Summary of Cytotoxicity Assay Results with Newcastle Disease Virus PPCONN70726**

10           Human tumor cells and normal cells were grown to approximately 80% confluence in 24 well tissue culture dishes. Growth medium was removed and PPCONN70726, a plaque purified clone of the mesogenic Newcastle disease virus strain Connecticut 70726-1946, was  
15           added in 10 fold dilutions ranging from 10<sup>7</sup> plaque forming units (PFU)/well to 1 PFU/well. Controls wells with no virus added were included on each plate. Virus was adsorbed for 90 minutes on a rocking platform at 37°C. At the end of the incubation period, the viral dilutions were removed and replaced by 1 ml of growth medium. Plates were then incubated for 5 days at 37°C in 5% CO<sub>2</sub>. Cytotoxicity was quantified by using a colorimetric MTT (2-  
20           [4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Cell Titer 96, catalog #G4000, Promega Corporation, Madison WI 53711) monitored at 570 nm, that detects mitochondrial enzyme activity (Mosman, T., 1983, J. Immunol. Methods 65:55). The viability in the virus treated wells was expressed as a percent of the activity in untreated control wells. The data was plotted graphically as PFU/well vs. viability as a percent of  
25           control. The IC<sub>50</sub> was calculated as the amount of virus in PFU/well causing a 50% reduction in the amount of viable cells.

**Table 22. Summary of Cytotoxicity Assay Results with PPCONN70726.**

| <u>Cell Type</u>           | <u>Cell Line</u> | <u>IC<sub>50</sub> (PFU/well)</u> |
|----------------------------|------------------|-----------------------------------|
| Head and Neck<br>Carcinoma | KB               | 18.1                              |
| Glioblastoma               | U87MG            | 12.7                              |
| Glioblastoma               | U373MG           | 879                               |
| Normal Fibroblast          | CCD922sk         | $7.3 \times 10^4$                 |

These results show that PPCONN70726 demonstrates tumor-selective killing of at least three different human tumor cells (KB, U87MG, and U373MG) relative to normal skin fibroblasts. The IC<sub>50</sub> values for the two tumor cell lines are between 80 and 5000-fold lower than that for normal cells.

### **Example 23**

#### **Intratumoral Treatment of HT1080 Fibrosarcoma Xenografts in Athymic Mice Using PPMK107, PPNJROAKIN, or PPCONN70726.**

In this experiment, athymic mice (female, NCR nu/nu, 5 to 6 weeks old) received a subcutaneous injection of  $10^7$  HT1080 tumor cells. Four days later when tumors reached a size range of 6 to 8.5 mm, mice were treated intratumorally with saline, PPMK107 (at  $1 \times 10^8$  PFU), PPNJROAKIN (at  $1 \times 10^8$  PFU), or PPCONN70726 (at  $1 \times 10^8$  PFU). As shown in Table 23 below, tumor regression was noted in mice treated with these three viruses (PPMK107, PPNJROAKIN, and PPCONN70726). After PPMK107 treatment of 12 mice, four experienced complete tumor regression and six experienced partial regression. After PPNJROAKIN treatment of 12 mice, one mouse experienced complete tumor regression and two experienced partial regression. After PPCONN70726 treatment of 12 mice, three experienced complete tumor regression and two experienced partial regression. No tumor regression was noted in any of the animals treated with saline.

**Table 23. Regression of HT1080 Fibrosarcoma Tumors in Athymic Mice After Treatment with One of Three Viruses (PPMK107, PPNJROAKIN and PPCONN70726) Each at a Dose of  $1 \times 10^8$  PFU.**

| Treatment   | # of Mice | Regression   |               |             |
|-------------|-----------|--------------|---------------|-------------|
|             |           | Partial (PR) | Complete (CR) | PR + CR (%) |
| PPMK107     | 12        | 6            | 4             | 10 (83%)    |
| PPNJROAKIN  | 12        | 2            | 1             | 3 (25%)     |
| PPCONN70726 | 12        | 2            | 3             | 5 (42%)     |
| Saline      | 11        | 0            | 0             | 0 ( 0%)     |

#### **Example 24**

**Effects of PPMK107, PPNJROAKIN, PPCONN70726 After Intracerebral Injection in Immunodeficient Athymic (nu/nu) and Immunocompetent Heterozygote (nu/+) Mice.**

Fifty-six athymic mice (nu/nu) and 56 immunocompetent heterozygote (nu/+) mice were given stereotaxic intracerebral injections with either saline, PPMK107, PPNJROAKIN, or PPCONN70726. Eight additional mice of each type were used as untreated controls. Viruses were used at one of two dose levels ( $2 \times 10^4$  or  $3.5 \times 10^6$  PFU/mouse). As shown in Table 24 below, all of the heterozygote nu/+ mice treated with each of the three viruses at the two dose levels survived through day 39 with the exception of one mouse at the lower PPCONN70726 dose level that was euthanized for non-neurological symptoms. Athymic nu/nu animals treated with either PPMK107 or PPCONN70726 had significantly less survival than the heterozygotes. This was especially true for the highest PPMK107 or PPCONN70726 virus dose of  $3.5 \times 10^6$  PFU/mouse where only 13% (1 of 8) of the athymic animals in each virus group survived through day 39. In contrast, there was 75% survival of the PPNJROAKIN-treated athymic mice at this same dose level ( $3.5 \times 10^6$  PFU/mouse). These data indicate that PPNJROAKIN is better tolerated in the brains of athymic mice than the other two virus strains.

**Table 24. Survival of Mice Following Intracerebral Injection of PPMK107, PPCONN70726, and PPNJROAKIN**

|       | Intracranial Injection | # of Mice | % Survival at Day 39 |
|-------|------------------------|-----------|----------------------|
| nu/+  | Untreated              | 8         | 100                  |
| nu/+  | Saline                 | 8         | 100                  |
| nu/+  | PPMK107, 2E+04         | 8         | 100                  |
| nu/+  | PPMK107, 3.5E+06       | 8         | 100                  |
| nu/+  | PPCONN70726, 2E+04     | 8         | 88 *                 |
| nu/+  | PPCONN70726, 3.5E+06   | 8         | 100                  |
| nu/+  | PPNJROAKIN, 2E+04      | 8         | 100                  |
| nu/+  | PPNJROAKIN, 3.5E+06    | 8         | 100                  |
|       |                        |           |                      |
| nu/nu | Untreated              | 8         | 100                  |
| nu/nu | Saline                 | 8         | 100                  |
| nu/nu | PPMK107, 2E+04         | 8         | 75                   |
| nu/nu | PPMK107, 3.5E+06       | 8         | 13                   |
| nu/nu | PPCONN70726, 2E+04     | 8         | 75                   |
| nu/nu | PPCONN70726, 3.5E+06   | 8         | 13                   |
| nu/nu | PPNJROAKIN, 2E+04      | 8         | 100                  |
| nu/nu | PPNJROAKIN, 3.5E+06    | 8         | 75                   |

\*- The one non-surviving mouse in this treatment group was euthanized for non-neurological symptoms.

5

### **Example 25**

#### **Summary of Cytotoxicity Assay Results with Sindbis Virus PPSINDBIS-Ar339**

Human tumor cells and normal cells were grown to approximately 80% confluence in 24 well tissue culture dishes. Growth medium was removed and PPSINDBIS-Ar339, a plaque purified clone of Sindbis Ar-339 was added in 10 fold dilutions ranging from  $10^7$  plaque forming units (PFU)/well to 1 PFU/well. Control wells with no virus added were included on each plate. Virus was adsorbed for 90 minutes on a rocking platform at 37°C. At the end of the incubation period, the viral dilutions were removed and replaced by 1 ml of growth medium. Plates were then incubated for 5 days at 37°C in 5% CO<sub>2</sub>. Cytotoxicity was

10



quantified by using a colorimetric MTT (2-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Cell Titer 96, catalog #G4000, Promega Corporation, Madison WI 53711) monitored at 570 nm, that detects mitochondrial enzyme activity (Mosman, T., 1983, J. Immunol. Methods 65:55). The viability in the virus treated wells was expressed as a percent of the activity in untreated control wells. The data was plotted graphically as PFU/well vs. viability as a percent of control. The IC<sub>50</sub> was calculated as the amount of virus in PFU/well causing a 50% reduction in the amount of viable cells.

**Table 25. Summary of Cytotoxicity Assay Results with PPSINDBIS-Ar339**

| <u>Cell Type</u>              | <u>Cell Line</u> | <u>IC<sub>50</sub> (PFU/well)</u> |
|-------------------------------|------------------|-----------------------------------|
| Pancreatic Carcinoma          | Panc-1*          | 69                                |
| Colorectal Carcinoma          | SW620*           | 13                                |
| Colorectal Carcinoma          | SW1463           | 1.8 x 10 <sup>5</sup>             |
| Non-small cell Lung carcinoma | A427             | >1 x 10 <sup>6</sup>              |
| Non-small cell Lung carcinoma | A549             | 5.2 x 10 <sup>4</sup>             |
| Renal carcinoma               | A498             | 2.4 x 10 <sup>4</sup>             |
| Renal carcinoma               | Caki-1           | 3.4 x 10 <sup>4</sup>             |
| Fibrosarcoma                  | HT1080           | 7.4 x 10 <sup>5</sup>             |
| Normal Keratinocyte           | NHEK             | 2.0 x 10 <sup>5</sup>             |
| Normal Fibroblast             | CCD922sk         | 1.6 x 10 <sup>5</sup>             |

\* Cells known to overexpress the mRNA for the high affinity laminin receptor.

The cellular receptor for Sindbis virus on mammalian cells is the high affinity laminin receptor, that is expressed mainly on cells of epithelial lineage, but is often overexpressed in many metastatic cancer cells like the Panc-1 pancreatic carcinoma line, and the SW620 colon adenocarcinoma cell line (Campo et al., (1992) Am. J. Pathol. 141, 1073-1083; Yow et al., (1988) Proc. Natl Acad Sci, 85, 6394-6398). In contrast, the rectal adenocarcinoma cell line SW1463 is known to express very low levels of high affinity laminin receptor mRNA (Yow et al., (1988) Proc. Natl Acad Sci, 85, 6394-6398), and is more than 4 order of magnitude more resistant to killing by PPSINDBIS-Ar339 than SW620 cells. These results demonstrate that cells that are tumorigenic and express high levels of the high affinity

laminin receptor are more sensitive to killing by Sindbis Clone PPSINDBIS-Ar339 than other tumor or normal cells.

### **Example 26**

#### **VSV Killing of Tumorigenic and Non-Tumorigenic Cells in the Presence of Interferon.**

In 96 well plates, tumorigenic KB and HT1080 cells ( $3 \times 10^4$  cells per well) and non-tumorigenic WISH cells ( $2.5 \times 10^4$  cells per well) were seeded in the presence of serially diluted interferon- $\alpha$  ranging from 2800 to 22 Units/ml and allowed to incubate for 24 hours at 37°C. The cells were then infected with vesicular stomatitis virus (VSV, Indiana strain) at an moi of 10. Controls were included for cells without interferon, and cells without interferon or virus. The cells were incubated at 37°C for 24 hours. Cytotoxicity was quantified by using a colorimetric MTT (2-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Cell Titer 96, catalog #G4000, Promega Corporation, Madison WI 53711) monitored at 570 nm, that detects mitochondrial enzyme activity (Mosman, T., 1983, J. Immunol. Methods 65:55). The viability in the virus treated wells was expressed as a percent of the activity in control wells not receiving virus.

**Table 26. Comparison of the Cell Killing Activity of VSV in Cells Treated with Exogenous Interferon.**

|               | Percent Viable Cells |        |    |
|---------------|----------------------|--------|----|
|               | WISH                 | HT1080 | KB |
| 0 U/ml IFN    | 0                    | 0      | 0  |
| 100 U/ml IFN  | 50                   | 6      | 0  |
| 1000 U/ml IFN | 95                   | 20     | 12 |

These results demonstrate that VSV is able to selectively kill tumor cells deficient in interferon responsiveness (see Example 27). WISH cells (human amnion cells) are a well established cell line for the use in interferon bioassays because of their ability to respond efficiently to interferons.

### **Example 27**

#### **Interferon Responsiveness in Cells Sensitive or Resistant to Killing by PPMK107.**

Individual cell lines were grown to near confluence in 96 well microtiter plates and treated with between 5 and 5000 U/ml of IFN $\alpha$ A for 24 hours. The cultures were then infected with PPMK107 at an moi of 1.0 and cultured for an additional 24 hours. Following

chemical fixation, the amount of viral expression was quantified by immunohistochemistry using a soluble indicator dye. The amount of virus growth is represented as the percent of P antigen expressed relative to control cells untreated with interferon (Figure 5). In this assay, interferon responsive cells manifest at least a 50% decrease in the viral antigen in response to interferon.

The results of this experiment show a strong correlation between the resistance of the cell line to the antiviral effects of exogenous interferon and the relative sensitivity of the cell to killing by PPMK107 (indicated by the IC<sub>50</sub> value shown in parentheses next to the cell line name in the graph legend, see Figure 5). For example, following pretreatment with 5 U/ml of interferon, 6 of 7 (86%) cell lines nonresponsive to interferon are sensitive to killing by PPMK107; when pretreated with 500 U/ml of interferon, all (4 of 4) of the nonresponsive cell lines are sensitive to killing by PPMK107.

The data above also present an example of a screening assay to identify candidate cells that are likely to be sensitive to killing by PPMK107 or other interferon-sensitive viruses. For example, infected cells expressing significant (e.g., more than 50% of controls) viral antigen following pretreatment with exogenous interferon would be considered interferon deficient and thereby sensitive to viral oncolysis.

### **Example 28**

#### **Use of a Desensitizing Intravenous Dose of PPMK107 to Reduce the Lethality of a Subsequent Intraperitoneal Dose of PPMK107.**

Mice were injected intravenously on day 0 with either saline or a desensitizing dose of PPMK107 ( $3 \times 10^8$  PFU/mouse). Two days later each set of mice were further subdivided into groups for intraperitoneal dosing with saline or PPMK107 (at doses of  $1 \times 10^9$ ,  $2.5 \times 10^9$ ,  $5 \times 10^9$ , and  $1 \times 10^{10}$  PFU/mouse). As shown in Table 27 below, when saline was used to pretreat the mice, deaths were recorded in the mice subsequently dosed with  $2.5 \times 10^9$ ,  $5 \times 10^9$ , and  $1 \times 10^{10}$  PFU. The doses of  $2.5 \times 10^9$ ,  $5 \times 10^9$  and  $1 \times 10^{10}$  PFU were 25%, 50% and 100% lethal, respectively, to the mice pretreated with saline. In contrast, using an IV desensitizing dose, no deaths were seen in the  $2.5 \times 10^9$  and  $5 \times 10^9$  PFU groups and only a 38% mortality was seen in the  $1 \times 10^{10}$  PFU group of mice. These data indicate that PPMK107 given by the intravenous route can be used to desensitize the toxicity of subsequent dosing of another route (namely in this example, the intraperitoneal route) with

this same agent. Furthermore, the maximal tolerated intraperitoneal dose of PPMK107 can be raised by approximately 5-fold when using this virus as a desensitizing agent.

**Table 27. Use of a Desensitizing Intravenous Dose of PPMK107 to Reduce the Lethality of a Subsequent Intraperitoneal Dose of PPMK107.**

| Group | IV Injection on Day 0 | IP Dose on Day 2 | # of Mice | # of Deaths | % Lethality |
|-------|-----------------------|------------------|-----------|-------------|-------------|
| 1     | Saline                | Saline           | 8         | 0           | 0           |
| 2     | Saline                | PPMK107, 1.0E+09 | 8         | 0           | 0           |
| 3     | Saline                | PPMK107, 2.5E+09 | 8         | 2           | 25          |
| 4     | Saline                | PPMK107, 5.0E+09 | 8         | 4           | 50          |
| 5     | Saline                | PPMK107, 1.0E+10 | 8         | 8           | 100         |
| 6     | PPMK107, 3E+08        | Saline           | 8         | 0           | 0           |
| 7     | PPMK107, 3E+08        | PPMK107, 1.0E+09 | 8         | 0           | 0           |
| 8     | PPMK107, 3E+08        | PPMK107, 2.5E+09 | 8         | 0           | 0           |
| 9     | PPMK107, 3E+08        | PPMK107, 5.0E+09 | 8         | 0           | 0           |
| 10    | PPMK107, 3E+08        | PPMK107, 1.0E+10 | 8         | 3           | 38          |

### Example 29

#### **Use of a Desensitizing Intravenous Dose of PPMK107 to Increase the Antitumor Efficacy a Subsequent Intraperitoneal Dose of PPMK107.**

In this example, athymic mice with visually apparent ascites tumors derived from the ES-2 human ovarian carcinoma cell line were treated with intraperitoneally with PPMK107 either with or without prior intravenous desensitization two days previously with  $3 \times 10^8$  PFU/mouse. As shown in Table 28, control mice treated intraperitoneally with saline rapidly died from ascites tumors with only 8% surviving by day 9 post treatment. Administering the maximum tolerated dose of PPMK107 intraperitoneally increased the survival percentage to 46% at day 9. Using IV desensitization, higher IP doses of PPMK107 such as  $2.5 \times 10^9$  and  $5.0 \times 10^9$  PFU can be tolerated and lead to almost a doubling of survival rate (83% and 79%, respectively) when compared to that achievable with the highest dose ( $1.0 \times 10^9$  PFU) without desensitization.

**Table 28. Survival of Mice with ES-2 Human Ovarian Carcinoma Ascites Tumors after Intraperitoneal PPMK107 Treatment**

| IP Treatment Group<br>(PFU/mouse) | Survival (Day 9)           | Survival (Day 9)        |
|-----------------------------------|----------------------------|-------------------------|
|                                   | Without IV Desensitization | With IV Desensitization |
| Saline                            | 2 out of 24 (8%)           | 3 out of 24 (13%)       |
| 1.0 E+09                          | 11 out of 24 (46%)         | 11 out of 24 (46%)      |
| 2.5 E+09 <i>a</i>                 | Dose Above MTD             | 20 out of 24 (83%)      |
| 5.0 E+09 <i>a</i>                 | Dose Above MTD             | 19 out of 24 (79%)      |

*a*- Dose above MTD without desensitization but below MTD with desensitization.

5

### Example 30

#### **Anti-Recombinant Murine TNF-alpha Antiserum Blocks IV Lethality of PPMK107 in Mice**

In this example, groups of 16 female C57BL/6 mice were dosed intravenously with  $5.0 \times 10^9$  PFU of PPMK107. Five hours previously different groups of 16 mice received either anti-recombinant murine TNF-alpha antiserum (100 ul from rabbits diluted 1:10 with saline), the equivalent amount of control rabbit serum or saline. As shown in Table 29 below, the lethality of PPMK107 at this dose is completely blocked using the rabbit antiserum against murine TNF-alpha.

10

15

**Table 29. Mortality of Mice Pretreated with Anti-Recombinant Murine TNF-Alpha Antiserum Before IV Dosing with 5.0E+09 of PPMK107.**

| PV701 Dose         | Pretreatment             | Mortality              |
|--------------------|--------------------------|------------------------|
| 2.5 E+09 PFU/mouse | Saline                   | 5 out of 16            |
|                    | Control Rabbit Serum     | 7 out of 16            |
|                    | Anti-rTNFalpha Antiserum | 0 out of 16 – <i>a</i> |

*a*- Mortality significantly different from saline and rabbit serum control treatment groups ( $P < 0.05$ , Fisher's Exact Test).

**Example 31****Purification of Clonal Viruses.**

A number of clonal RNA viruses were purified by either ultracentrifugation of the virus without pelleting or by sequential tangential flow filtration. For purification by one of the following methods:

Method 1: As in Method A of Example 15.

Method 2: As in Method D of Example 15.

Method 3: Vero cells at approximately 70% confluence were infected at an moi of 0.01 and incubated at 37°C for 18 hours. The flasks containing the infected cells were frozen at -70°C. The cell were thawed at room temperature and then maintained on ice until harvest. For harvest, the cells were scraped into the media present during the infection and clarified at 1750 x g for 30 minutes at 4°C. The clarified supernatants were pooled and layered over a 20%/55% discontinuous gradient and centrifuged at approximately 100,000 x g for 30 minutes. The purified virus was harvested from the sucrose 20%/55% interface and dialyzed against calcium- and magnesium-free PBS to remove the sucrose.

The activity of the virus preparations was determined by the plaque assay method using HT1080 cells for Newcastle disease virus and Vero cells for Vesicular stomatitis strains. The protein content of the virus preparations was determined using the NanoOrange Protein Quantification Kit (Molecular Probes, Inc., Eugene, OR) with bovine serum albumin as the protein standard.

**Table 30. Specific Activity of a Number of Clonal RNA Viruses Purified by Ultracentrifugation without Pelleting or Tangential Flow Filtration.**

| <b>Virus</b>                        | <b>Virus Clone</b> | <b>Purification Method</b> | <b>Specific Activity (PFU/mg protein)</b> |
|-------------------------------------|--------------------|----------------------------|---|
| Newcastle disease-MK107 strain      | PPMK107            | 1                          | 1.3E+11                                   |
| Newcastle disease-MK107 strain      | PPMK107            | 2                          | 1.0E+11                                   |
| Newcastle disease-Roakin strain     | PPNJROAKIN         | 1                          | 1.0E+11                                   |
| Newcastle disease-ConnH strain      | PPCONN70726        | 1                          | 2.1E+10                                   |
| Vesicular Stomatitis-Indiana strain | PPVSV              | 3                          | 4.5E+9                                    |

5            These results demonstrate the ability to purify different clonal RNA viruses to high specific activity using the methods described in this invention.

### **Example 32**

**Sindbis Virus PPSINDBIS-Ar339 Causes Tumor Inhibition in Athymic Mice with Human Tumor Cell Xenografts.**

10            Athymic mice were injected subcutaneously with 10 million SW620 human adenocarcinoma tumor cells. Five days later the tumors (average size = 78 mm<sup>3</sup>) were treated with a single injection of PPSINDBIS-Ar339 (10 mice, 5 x 10<sup>6</sup> PFU) or saline (9 mice). Tumor size and mouse weight were measured twice per week until study termination. By the  
15            twelfth day after treatment the average tumor size of the saline treated mice had increased by an average of 896% (from 71.3 mm<sup>3</sup> to 639.1 mm<sup>3</sup>).

**Table 31. Intratumoral treatment of SW620 Colon Adenocarcinoma Human Xenografts with PPSINDBIS-Ar339.**

| Time Post Treatment | Tumor Growth Inhibition <sup>a</sup> |
|---------------------|--------------------------------------|
| 5 days              | 89%                                  |
| 9 days              | 90%                                  |
| 12 days             | 87%                                  |

<sup>a</sup> - % tumor growth inhibition =  $\frac{\% \text{ increase control group} - \% \text{ increase Tx group}}{\% \text{ increase control group}} \times 100$

These data show that a single injection of PPSINDBIS-Ar339 results in significant tumor growth inhibition compared to treatment with saline. Treatment with PPSINDBIS-Ar339 was also well tolerated by the mice as evidenced by the absence of weight loss in either the saline or virus treated groups.

### Example 33

#### **Viruses Belonging to Unrelated Families Have Similar Activity on Human Tumor Cell Lines.**

Cytotoxicity assays were performed with the SW620 adenocarcinoma cell line and PPMK107 (Paramyxovirus family) or PPSINDBIS-Ar339 (Togavirus family) as described in Examples 1 and 25 (see Fig. 6). These two unrelated viruses use distinct receptors to enter the host cell and replicate by mechanisms unique to each virus. Nevertheless, the response of the SW620 cell line to infection by these two viruses is remarkably similar indicating that the mechanisms of tumor cell killing by these viruses share common elements.

### Example 34

#### **Use of PPMK107 in Combination with Chemotherapy for the Systemic Treatment of Human Tumor Xenografts in Athymic Mice**

Athymic mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells. After tumors reached a size range from between 5 and 7 mm, mice were randomized into treatment groups. Mice received intraperitoneal injections saline vehicle on treatment days 0, 2 and 4. PPMK107 at a dose of  $2 \times 10^7$  PFU or saline vehicle was administered by



intravenous injection on treatment day 2 only, one hour after the intraperitoneal injection. Carboplatin (carbo) at a dose of 160 mg/kg was administered by intraperitoneal injection on treatment day 0, 2, or 4 as indicated. The percent of each group with complete regression (CR) and partial regression (PR) is shown. Each treatment group had 9 tumor-bearing mice.

5

**Table 32. PPMK107 in Combination with Carboplatin for the Systemic Treatment of Subcutaneous Human HT1080 Fibrosarcoma Xenografts in Athymic Mice.**

| Treatment                      | CR+PR (%) |
|--------------------------------|-----------|
| Saline, days 0, 2 and 4        | 0         |
| PPMK107, day 2                 | 44        |
| Carbo, day 0                   | 0         |
| Carbo, day 2                   | 11        |
| Carbo, day 3                   | 11        |
| PPMK107, day 2<br>Carbo, day 0 | 67        |
| PPMK107, day 2<br>Carbo, day 2 | 78        |
| PPMK107, day 2<br>Carbo, day 4 | 55        |

These results in Table 32 indicate that subcutaneous HT1080 tumors are responsive to IV treatment with PPMK107 and that addition of carboplatin two days before, the same day, or two days after PPMK107 treatment resulted in a higher percentage of tumor regression (CR + PR) than either PPMK107 alone or carboplatin alone.

### Example 35

#### 15 **Second Experiment on the Use of PPMK107 in Combination with Carboplatin for the Systemic Treatment of Human HT1080 Tumor Xenografts in Athymic Mice**

Athymic mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells as in Example 34. Mice received intraperitoneal injections carboplatin (carbo) at a dose of 80 mg/kg or 120 mg/kg or saline vehicle on treatment day 0 followed by intravenous injection of PPMK107 (at  $6 \times 10^6$  or  $2 \times 10^7$  PFU) on treatment day 2. The percent of each

20

group with complete regression (CR) and partial regression (PR) is shown. Each treatment group had 9 tumor-bearing mice.

**Table 33. PPMK107 in Combination with Carboplatin for the Systemic Treatment of Subcutaneous Human HT1080 Fibrosarcoma Xenografts in Athymic Mice.**

| Treatment        | Dose                   | CR+PR (%) |
|------------------|------------------------|-----------|
| Saline           |                        | 0         |
| PPMK107          | 6E+06 PFU              | 22        |
| PPMK107          | 2E+07 PFU              | 56        |
| Carbo            | 80mg/kg                | 33        |
| Carbo            | 120mg/kg               | 22        |
| PPMK107<br>Carbo | 6E+06 PFU<br>80 mg/kg  | 78        |
| PPMK107<br>Carbo | 6E+06 PFU<br>120 mg/kg | 44        |
| PPMK107<br>Carbo | 2E+07 PFU<br>80 mg/kg  | 67        |
| PPMK107<br>Carbo | 2E+07 PFU<br>120 mg/kg | 100       |

These results in Table 33 indicate that subcutaneous HT1080 tumors are responsive to IV treatment with PPMK107 at each dose level and that addition of carboplatin at either dose level two days before PPMK107 treatment resulted in a higher percentage of tumor regression (CR + PR) than either PPMK107 alone or carboplatin alone.

### Example 36

#### **Third Experiment on the Use of PPMK107 in Combination with Carboplatin for the Systemic Treatment of Human HT1080 Tumor Xenografts in Athymic Mice**

Athymic mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells as in Example 34. Mice received intraperitoneal injections carboplatin (carbo) at a dose of 60 mg/kg or saline vehicle on treatment day 0 followed by intravenous injection of

PPMK107 (at  $6 \times 10^6$  PFU) on treatment day 2. The percent of each group with complete regression (CR) and partial regression (PR) is shown. Each treatment group had 9 tumor-bearing mice except for the carboplatin only group which had 8 mice.

5      **Table 34. PPMK107 in Combination with Carboplatin for the Systemic Treatment of Subcutaneous Human HT1080 Fibrosarcoma Xenografts in Athymic Mice.**

| Treatment        | CR+PR (%) |
|------------------|-----------|
| Saline           | 0         |
| PPMK107          | 44        |
| Carbo            | 25        |
| PPMK107<br>Carbo | 89        |

10      These results in Table 34 indicate that subcutaneous HT1080 tumors are responsive to IV treatment with PPMK107 and that addition of carboplatin two days before PPMK107 treatment resulted in a higher percentage of tumor regression (CR + PR) than either PPMK107 alone or carboplatin alone.

#### Example 37

15      **Use of a Corticosteroid (Dexamethasone) to Reduce the Lethality of an Intravenous Dose of PPMK107.**

20      Female athymic mice (six to seven weeks old) were injected intraperitoneally on days 0, 1, 2, 3 and 4 with either dexamethasone (one group at a dose of 25 mg/kg and another group at 10 mg/kg) or saline. All animals were given an intravenous dose of PPMK107 ( $3 \times 10^9$  PFU/mouse) on day 2 (one hour following the IP dose of dexamethasone or saline). Mice were observed and the lethality tabulated in Table 33 below.

**Table 35. Use of Dexamethasone to Reduce the Lethality of an Intravenous Dose of PPMK107.**

| Group | IP Treatment on Days 0,1,2,3,and 4 | IV Treatment on Day 2 | Lethality (%) |
|-------|------------------------------------|-----------------------|---------------|
| 1     | Dexamethasone (25 mg/kg)           | PPMK107, 3.0E+09      | 7             |
| 2     | Dexamethasone (10 mg/kg)           | PPMK107, 3.0E+09      | 0             |
| 3     | Saline                             | PPMK107, 3.0E+09      | 67            |

The PPMK107 dose of  $3 \times 10^9$  was lethal to 67% of the mice given saline control IP dosing. Dexamethasone markedly reduced lethality due to PPMK107 with only 7% mortality observed in the animals given 25 mg/kg and 0% mortality observed in the animals given 10 mg/kg. These data indicate that a corticosteroid like dexamethasone can be used to reduce the toxicity of an intravenous dose of PPMK107.

\* \* \*

The foregoing is intended as illustrative of the present invention but not limiting. Numerous variations and modifications may be effected without departing from the true spirit and scope of the invention.

**WHAT IS CLAIMED IS:**

1. A method of infecting a neoplasm in a mammal with a virus comprising administering an interferon-sensitive, replication-competent clonal RNA virus to said mammal.

5 2. A method of infecting a neoplasm in a mammal with a virus comprising administering a replication-competent clonal RNA virus to said mammal wherein said virus has sensitivity to interferon.

10 3. A method of treating a neoplasm in a mammal comprising administering to said mammal a therapeutically effective amount of an interferon-sensitive, replication-competent clonal RNA virus.

15 4. A method as in claim 1 wherein said RNA virus replicates at least 100-fold less in the presence of interferon compared to in the absence of interferon.

5. A method as in claim 1 wherein said RNA virus replicates at least 1000-fold less in the presence of interferon compared to in the absence of interferon.

20 6. A method as in claim 1 wherein said administering step is systemic.

7. A method as in claim 1 wherein said neoplasm is a cancer.

8. A method as in claim 1 wherein said mammal is a human.

25 9. A method as in claim 1 wherein said clonal virus is plaque purified.

10. A method as in claim 1 wherein said clonal virus is of recombinant clonal origin.

30 11. A method as in claim 1 wherein said RNA virus is a Paramyxovirus.

12. A method as in claim 11 wherein said Paramyxovirus is purified to a level of at least  $2 \times 10^9$  PFU per mg of protein.

***SUBSTITUTE SHEET (RULE 26)***

13. A method as in claim 11 wherein said Paramyxovirus is purified to a level of at least  $1 \times 10^{10}$  PFU per mg of protein.
- 5 14. A method as in claim 11 wherein said Paramyxovirus is purified to a level of at least  $6 \times 10^{10}$  PFU per mg of protein.
- 15 15. A method as in claim 11 wherein said Paramyxovirus is purified to a level in which the particle per PFU ratio is no greater than 5.
- 10 16. A method as in claim 11 wherein said Paramyxovirus is purified to a level in which the particle per PFU ratio is no greater than 3.
- 15 17. A method as in claim 11 wherein said Paramyxovirus is purified to a level in which the particle per PFU ratio is no greater than 1.2.
18. A method as in claim 11 wherein said Paramyxovirus is avian paramyxovirus type 2.
- 20 19. A method as in claim 11 wherein said Paramyxovirus is NDV.
20. A method as in claim 11 wherein said Paramyxovirus is mumps virus.
21. A method as in claim 11 wherein said Paramyxovirus is human parainfluenza virus.
- 25 22. A method as claim 1 wherein said RNA virus is selected from the group consisting of a Rhabdovirus, Togavirus, Flavivirus, Reovirus, Picornavirus, and Coronavirus.
23. A method as in claim 22 wherein said Togavirus is Sindbis virus.
- 30 24. A method as in claim 22 wherein said Reovirus has a modification at omega 3.
25. A method as in claim 22 wherein said Reovirus has an attenuating mutation at omega 1.

26. A method as in claim 22 wherein said Reovirus is an attenuated rotavirus

27. A method as in claim 26 wherein said rotavirus is rotavirus WC3.

5 28. A method of infecting a neoplasm in a mammal with a virus comprising administering an interferon-sensitive, replication-competent clonal vaccinia virus, having one or more mutations in one or more genes selected from the group consisting of K3L, E3L, and B18R, to said mammal.

10 29. A method of infecting a neoplasm in a mammal with a virus comprising administering a replication-competent clonal vaccinia virus, having one or more mutations in one or more genes selected from the group consisting of K3L, E3L, and B18R, to said mammal wherein said virus has sensitivity to interferon.

15 30. A method treating a neoplasm in a mammal comprising administering to said mammal a therapeutically effective amount of an interferon-sensitive, replication-competent clonal vaccinia virus, having one or more mutations in one or more genes selected from the group consisting of K3L, E3L, and B18R.

20 31. A method as in claim 30 wherein said mammal is a human.

32. A method as in claim 30 wherein said vaccinia virus is a vaccinia virus having an attenuating mutation in a gene selected from the group encoding vaccinia growth factor, thymidine kinase, thymidylate kinase, DNA ligase, ribonucleotide reductase and dUTPase.

25

33. A method of infecting a neoplasm in a mammal with a virus comprising administering an interferon-sensitive, replication-competent clonal DNA virus, selected from the group consisting of Adenoviruses, Parvoviruses, Papovaviruses, and Iridoviruses, to said mammal.

30 34. A method of infecting a neoplasm in a mammal with a virus comprising administering a replication-competent clonal DNA virus, selected from the group consisting of Adenoviruses, Parvoviruses, Papovaviruses, and Iridoviruses, to said mammal wherein said virus has sensitivity to interferon.

35. A method of treating a neoplasm in a mammal comprising administering to said mammal a therapeutically effective amount of an interferon-sensitive, clonal DNA virus selected from the group consisting of Adenoviruses, Parvoviruses, Papovaviruses, and Iridoviruses.

5

36. A method as in claim 33 wherein said mammal is a human.

37. A method as in claim 33 wherein said Adenovirus virus has a modification in the VA1 transcripts causing said Adenovirus to become interferon-sensitive.

10

38. A method as in claim 37 wherein said Adenovirus virus is selected from the group consisting of vaccine strains of Ad-4, Ad-7 and Ad-21.

15

39. A method of infecting a neoplasm in a mammal with a virus comprising administering an interferon-sensitive, replication-competent clonal Herpesvirus to said mammal.

40. A method of infecting a neoplasm in a mammal with a virus comprising administering a replication-competent clonal Herpesvirus to said mammal wherein said virus has sensitivity to interferon.

20

41. A method treating a neoplasm in a mammal comprising administering to said mammal a therapeutically effective amount of an interferon-sensitive, replication-competent clonal Herpesvirus.

25

42. A method as in claim 41 wherein said Herpesvirus is a member of the subfamily Betaherpesvirus or subfamily Gammaherpesvirus.

43. A method as in claim 41 wherein said Herpesvirus is a member of the subfamily Alphaherpesvirus that is not HSV-1.

30

44. A method as in claim 41 wherein said mammal is a human.



45. A method as in claim 41 wherein said Herpesvirus is a member of the subfamily Alphaherpesvirus which has decreased expression of the (2'-5')An analog.

46. A method as in claim 45 wherein said Herpesvirus is a Herpesvirus having an attenuating mutation selected from the group consisting of the genes encoding thymidine kinase,  
5 ribonucleotide reductase, or a deletion in the b'a'c' inverted repeat locus.

47. A method as in claim 45 wherein said Herpesvirus has a modification in the gamma 34.5 gene.

10 48. A method as in claim 41 wherein said Herpesvirus has a modification in the gamma 34.5 gene and an attenuating mutation in the gene encoding of thymidine kinase, or a deletion in the b'a'c' inverted repeat locus or functionally analogous loci.

15 49. A method as in claim 41 wherein said Herpesvirus is a Herpesvirus having an attenuating mutation in a gene selected from the group consisting of thymidine kinase, and ribonucleotide reductase, or a deletion in the b'a'c' inverted repeat locus.

20 50. A method as in claim 1 wherein said neoplasm is a cancer selected from the group consisting of lung, colon, prostate, breast and brain cancer.

51. A method as in claim 1 wherein said neoplasm is a solid tumor.

52. A method as in claim 50 wherein said brain cancer is a glioblastoma.

25 53. A method as in claim 1 wherein said virus contains a gene encoding interferon to permit the viral expression of interferon.

54. A method as in claim 1 wherein said virus contains a gene encoding a pro-drug activating enzyme.

30 55. A method as in claim 1 further comprising administering IFN, before, during or after administration of said virus.

56. A method as in claim 55 wherein said interferon is selected from the group consisting of IFN, -IFN, -IFN, -IFN, and synthetic consensus forms of IFN.

57. A method as in claim 1 further comprising administering a tyrosine kinase inhibitor before, during or after administration of said virus.

58. A method as in claim 1 further comprising administering a compound selected from the group of compounds comprising a purine nucleoside analog, tyrosine kinase inhibitor, cimetidine, and mitochondrial inhibitors.

59. A method as in claim 1 further comprising administering a chemotherapeutic agent before, during or after administration of said virus.

60. A method as in claim 1 further comprising administering a cytokine before, during or after administration of said virus.

61. A method as in claim 1 further comprising administering an immunosuppressant before, during or after administration of said virus.

62. A method as in claim 1 further comprising administering a viral replication controlling amount of a compound selected from the group consisting of IFN, ribavirin, acyclovir, famciclovir, and ganciclovir.

63. A method as in claim 1 wherein said administration is intravenous or intratumoral.

64. A method of infecting a neoplasm which is at least 1 centimeter in size in a mammal with a virus comprising administering a clonal virus, selected from the group consisting of (1) RNA viruses; (2) Hepadenavirus; (3) Parvovirus; (4) Papovavirus; (5) Herpesvirus; (6) Poxvirus; and (7) Iridovirus, to said mammal.

65. A method of treating a neoplasm in a mammal, comprising administering to said mammal a therapeutically effective amount of a clonal virus selected from the group consisting of (1)

RNA virus; (2) Hepadenavirus; (3) Parvovirus; (4) Papovavirus; (5) Herpesvirus; (6) Poxvirus; and (7) Iridovirus, wherein said neoplasm is at least 1 centimeter in size.

66. A method as in claim 64, wherein said neoplasm is at least  $300 \text{ mm}^3$  in volume.

67. A method as in claim 64, wherein said RNA virus is a Paramyxovirus.

68. A method as in claim 67, wherein said Paramyxovirus is NDV.

69. A method as in claim 64, wherein said mammal is a human.

70. A method as in claim 64, wherein said administration is intravenous or intratumoral.

71. A method as in claim 64, wherein said paramyxovirus is purified to a level of at least  $2 \times 10^9$  PFU per mg protein.

72. A method as in claim 68, wherein said NDV is mesogenic.

73. A method as in claim 65 wherein said neoplasm is cancerous.

74. A method of treating a tumor in a mammal, comprising administering to said mammal a therapeutically effective amount of an RNA virus cytotoxic to said tumor, wherein said mammal has a tumor burden comprising at least 1.5% of the total body weight of said mammal.

75. A method as in claim 74, wherein said tumor does not respond to chemotherapy.

76. A method of screening tumor cells or tissue freshly removed from the patient to determine the sensitivity of said cells or tissue to killing by a virus comprising subjecting a tissue sample to a differential cytotoxicity assay using an interferon-sensitive virus.

77. A method as in claim 76 further comprising the step of screening said cells or tissue for protein, or mRNA encoding protein, selected from the group consisting of p68 protein kinase, C-Myc, C-Myb, ISGF-3, IRF-1, IFN receptor, and p58, Ras overexpression, Ras with

activating mutations, overexpression of other mediators of the Ras signaling pathway, unregulated receptor tyrosine kinases.

78. A method for identifying a virus with antineoplastic activity in a mammal comprising:

- a) using said test virus to infect i) cells deficient in an interferon-mediated antiviral activity, and ii) cells competent in an interferon-mediated antiviral activity, and
- b) determining whether said test virus kills said cells deficient in an interferon-mediated antiviral activity preferentially to said cells competent in interferon-mediated antiviral activity.

79. A method as in claim 78 wherein said cells deficient in an interferon-mediated antiviral activity are KB human head and neck carcinoma cells.

80. A method as in claim 78 wherein said cells competent in an interferon-mediated antiviral activity are human skin fibroblasts.

81. A method of making viruses for use in antineoplastic therapy comprising:

- a) modifying an existing virus by diminishing or ablating a viral mechanism for the inactivation of the antiviral effects of IFN, and optionally
- b) creating an attenuating mutation

82. A method of controlling viral replication in a mammal treated with a virus selected from the group consisting of RNA viruses, Adenoviruses, Poxviruses, Iridoviruses, Parvoviruses, Hepadnaviruses, Varicellaviruses, Betaherpesviruses, and Gammaherpesviruses comprising administering an antiviral compound.

83. A method as in claim 82 wherein said antiviral compound is interferon.

84. A method as in claim 82 wherein said antiviral is selected from the group consisting of ribavirin, acyclovir, famciclovir, and ganciclovir.

85. A method as in claim 82 wherein said antiviral is a neutralizing antibody to said virus.

86. A clonal Paramyxovirus purified by ultracentrifugation without pelleting.

87. A clonal Paramyxovirus purified to a level of at least  $2 \times 10^9$  PFU/mg protein.

5 88. A Paramyxovirus as in claim 87 wherein said paramyxovirus is grown in eggs and is substantially free of contaminating egg proteins.

89. A Paramyxovirus as in claim 87 wherein said paramyxovirus has a particle per PFU ratio no greater than 5.

10

90. A Paramyxovirus as in claim 87 wherein said paramyxovirus has a particle per PFU ratio no greater than 3.

15

91. A Paramyxovirus as in claim 87 wherein said paramyxovirus has a particle per PFU ratio no greater than 1.2.

92. A clonal Paramyxovirus purified to a level of at least  $1 \times 10^{10}$  PFU/mg protein.

93. A clonal Paramyxovirus purified to a level of at least  $6 \times 10^{10}$  PFU/mg protein.

20

94. A Paramyxovirus as in claim 87 wherein said virus is cytotoxic.

95. A Paramyxovirus as in claim 87 wherein said Paramyxovirus is Newcastle disease virus.

25

96. An NDV as in claim 95 wherein said NDV is cytotoxic.

97. An NDV as in claim 95 wherein said NDV is mesogenic.

98. A clonal RNA virus purified to a level of at least  $2 \times 10^9$  PFU/mg protein.

30

99. An RNA virus as in claim 98 wherein said virus is replication-competent.

100. A replication-competent cytocidal virus which is interferon-sensitive and purified to a level of at least  $2 \times 10^9$  PFU/mg protein.

101. A cytocidal virus as in claim 100 wherein said virus is clonal.

102. A clonal cytocidal DNA virus which is interferon-sensitive and purified to a level of at least  $2 \times 10^9$  PFU/mg protein.

103. A cytocidal DNA virus as in claim 102 wherein said virus is a Poxvirus.

104. A Poxvirus as in claim 103 wherein said Poxvirus is a vaccinia virus having one or more mutations in one or more genes selected from the group consisting of K3L, E3L, and B18R.

105. A replication-competent vaccinia virus having a) one or more mutations in one or more of the K3L, E3L and B18R genes, and b) an attenuating mutation in one or more of the genes encoding thymidine kinase, ribonucleotide reductase, vaccinia growth factor, thymidylate kinase, DNA ligase, dUTPase.

106. A replication-competent vaccinia virus having one or more mutations in two or more genes selected from the group consisting of K3L, E3L, and B18R.

107. A Herpesvirus having a modification in the expression of the (2'-5')A analog.

108. A Reovirus having a mutation at omega 3 and purified to a level of at least  $2 \times 10^9$  PFU/mg protein.

109. A Reovirus having mutations at omega 1 and omega 3.

110. A method of purifying an RNA virus comprising the steps of:

a) generating a clonal virus, and

b) purifying said clonal virus by ultracentrifugation without pelleting.

111. A method as in claim 110 wherein said RNA virus is replication-competent.

112. A method of purifying a Paramyxovirus comprising purifying said virus by ultracentrifugation without pelleting.

113. A method as in claim 112 wherein said purifying step additionally comprises prior to said  
5 ultracentrifugation:

- a) plaque purifying to generate a clonal virus,
- b) inoculating eggs with said clonal virus,
- c) incubating said eggs,
- d) chilling said eggs,
- 10 e) harvesting allantoic fluid from said eggs and,
- f) removing cell debris from said allantoic fluid.

114. A method as in claim 112 wherein said Paramyxovirus virus is NDV.

15 115. A method of infecting a neoplasm in a mammal with a virus comprising administering an interferon-sensitive, replication-competent RNA virus to said mammal.

116. A method as in claim 1 wherein said virus is selected from the group consisting of the  
Newcastle disease virus strain MK107, Newcastle disease virus strain NJRoakin, Sindbis  
20 virus, and Vesicular stomatitis virus.

117. A method of infecting a neoplasm in a mammal with a virus comprising administering a  
clonal virus selected from the group consisting of the Newcastle disease virus strain  
MK107, Newcastle disease virus strain NJRoakin, Sindbis virus, and Vesicular stomatitis  
virus.

25 118. A method as in claim 1 or claim 28 or claim 33 wherein said virus is administered as more  
than one dose.

119. A method as in claim 118 wherein the first dose is a desensitizing dose.

30 120. A method as in claim 119 wherein said first dose is administered intravenously and a  
subsequent dose administered intravenously.

121. A method as in claim 119 wherein said first dose is administered intravenously and a subsequent dose administered intraperitoneally.

5 122. A method as in claim 119 wherein said first dose is administered intravenously and a subsequent dose administered intra-arterially.

123. A method of treating a neoplasm in a mammal comprising subjecting a sample from said mammal to an immunoassay to detect the amount of virus receptor present, and if said receptor is present, administering an interferon-sensitive, replication competent clonal virus, which bind said receptor, to said mammal.

10

124. A method as in claim 123 herein said virus is Sindbis and said receptor is the high affinity laminin receptor.

15 125. A method as in claim 1 or claim 28 or claim 33 wherein said virus is administered over the course of at least 4 minutes.

126. A method of treating tumor ascites comprising administering an interferon-sensitive, replication-competent clonal virus.

20

127. A method of reducing pain in a mammal comprising administering an interferon-sensitive, replication competent clonal virus.

25 128. A method as in claim 1 wherein said virus is administered over a period of at least 20 minutes.

129. A method as in claim 1 wherein said virus dose is at least  $5.9 \times 10^9$  PFU/m<sup>2</sup>.

30 130. A method as in claim 1 wherein said virus dose is at least  $9.6 \times 10^{10}$  PFU/m<sup>2</sup>.

131. A method as in claim 1 wherein said virus is at a level of purity of at least  $3 \times 10^9$  PFU/mg protein.



132. A method as in claim 120 wherein said subsequent dose is at least  $4.8 \times 10^{10}$  PFU/m<sup>2</sup>.

133. A method as in claim 120 wherein said subsequent dose is at least  $9.6 \times 10^{10}$  PFU/m<sup>2</sup>.

134. A method of infecting a neoplasm in a mammal comprising administering a virus selected from the group of families consisting of Paramyxoviridae, Orthomyxoviridae, Rhabdoviridae, Togaviridae, Flaviviridae, Picornaviridae, Coronaviridae, Reoviridae, Poxviridae, Herpesviridae, and Parvoviridae

135. A method as in claim 134 wherein said Togavirus is Sindbis virus.

136. A method as in claim 1 wherein said RNA virus is a single-stranded RNA virus.

137. A method of treating a disease of viral etiology in a mammal comprising administering to said mammal a therapeutically effective amount of a replication-competent clonal virus.

138. A method as in claim 136 wherein said administering step is systemic.

139. A method as in claim 137 wherein said disease is caused by a virus selected from the group consisting of hepatitis B virus, hepatitis C virus, or human immunodeficiency virus.


140. A method as in claim 137 wherein said virus is a Paramyxovirus.

141. A method as in claim 137 wherein said RNA virus is selected from the group consisting of a Rhabdovirus, Togavirus, Flavivirus, Picornavirus, and Coronavirus.

142. A method as in claim 137 wherein said RNA virus is selected from the group consisting of a DNA virus, selected from the group consisting of Adenoviruses, Parvoviruses, Papovaviruses, and Iridoviruses, to said mammal.

143. A method as in claim 1 wherein further comprising screening said neoplasm for protein, or mRNA encoding protein, selected from the group consisting of p68 protein kinase, C-Myc, C-Myb, ISGF-3, IRF-1, IFN receptor, and p58, Ras overexpression, Ras with activating


2/6

**FIG. 2**


3/6

**FIG. 3**


Effect of IFN on CCD Cells




Effect of IFN on KB Cells




4/6

**FIG. 4**

5/6

**FIG. 5****Antiviral Effect of IFN in Various Cell Lines**

6/6

**FIG. 6*****SUBSTITUTE SHEET (RULE 26)***

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 October 2000 (26.10.2000)

PCT

(10) International Publication Number  
**WO 00/062735 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/70**,  
A01N 65/00, 63/00

Reid, W. [US/US]; 8310 Fox Run, Potomac, MD 20854 (US).

(21) International Application Number: PCT/US00/10204

(74) Agent: **BYRNE, Thomas, E.**; Nixon & Vanderhye P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).

(22) International Filing Date: 17 April 2000 (17.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/292,376 15 April 1999 (15.04.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 09/292,376 (CIP)  
Filed on 15 April 1999 (15.04.1999)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **PRO-VIRUS, INC.** [US/US]; 16020 Industrial Drive, Gaithersburg, MD 20877 (US).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ROBERTS, Michael, S.** [US/US]; 105 Colony Court, Walkersville, MD 21793 (US). **LORENCE, Robert, M.** [US/US]; 9506 Nowell Drive, Bethesda, MD 20817 (US). **GROENE, William, S.** [US/US]; 5746 Windsong Court, New Market, MD 21774 (US). **RABIN, Harvey** [US/US]; 11021 Ralston Road, Rockville, MD 20852 (US). **VON BORSTEL,**

(88) Date of publication of the international search report:  
27 November 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: TREATMENT OF NEOPLASMS WITH VIRUSES

(57) Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.

WO 00/062735 A3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/10204

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/70; A01N 65/00, 63/00

US CL : 514/44; 424/93.1, 93.2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/44; 424/93.1, 93.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EAST, BIOSIS, CAPLUS, CANCERLIT, SCIENSEARCH, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category *    | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.   |
|---------------|--|---|
| X<br>---<br>Y | WO 94/25627 A1 (LORENCE) 10 November 1994 (10.11.94). See abstract and entire document.  | 1-17, 19, 50-52, 55,<br>56, 58-63, 115-122,<br>126, 127, 134, 136<br>-----<br>18, 20, 21, 64-75,<br>123, 125, 128-133,<br>145-156 |
| X             | OKUNO, Y. et al. Studies on the use of mumps virus for treatment of human cancer. Biken J. 1978, Vol. 21, No. 2, pages 37-49.  | 1, 11, 20, 140  |
| X             | US 5,688,773 A (CHIOCCA et al) 18 November 1997 (18.11.97) See abstract and column 16, lines 4-20.   | 1, 22, 53, 54, 57, 58,<br>136<br>-----<br>64-66   |
| Y             | IKEDA et al, Detection of heterozygous mutation in the retinoblastoma gene in a human pituitary adenoma using PCR-SSCP analysis and direct sequencing. Endocr Pathol. 1995, Vol. 6, pages 189-196. | 1, 143  |



Further documents are listed in the continuation of Box C.



See patent family annex.

|   |  |
|---|--|
| * Special categories of cited documents:  | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| "A" document defining the general state of the art which is not considered to be of particular relevance  | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| "E" earlier application or patent published on or after the international filing date   | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" document member of the same patent family  |
| "O" document referring to an oral disclosure, use, exhibition or other means  |  |
| "P" document published prior to the international filing date but later than the priority date claimed  |  |

Date of the actual completion of the international search

05 September 2003 (05.09.2003)

Date of mailing of the international search report

07 OCT 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Q. Janice Li

Telephone No. 703-308-0196



## INTERNATIONAL SEARCH REPORT

PCT/US00/10204

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| Y          | ZHANG et al, Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Therapy, 1996, Vol. 3, No. 1, pages 31-38. | 53, 55, 56            |

Form PCT/ISA/210 (second sheet) (July 1998)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/10204

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 1-75, 115-136, 143-156
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

PCT/US00/10204

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING**

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I. Claims 1-75, 115-136, and 143-156, drawn to a method of infecting a neoplasm with an interferon-sensitive, replication-competent clonal virus in a mammal.

Groups II. Claims 76 and 77, drawn to a method of screening tumor cells for sensitivity to a virus.

Groups III. Claims 78-80, drawn to a method of identifying a virus with anti-neoplastic activity.

Groups IV. Claim 81, drawn to a method of preparing an attenuated virus.

Group V. Claims 82-85, drawn to a method of controlling viral replication.

Group VI. Claims 86-114, drawn to isolated RNA viruses, and methods of purifying RNA viruses.

Group VII. Claims 137-141, drawn to a method of treating a viral disease with a replication-competent clonal virus.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

Each of the invention groups I, VI, and VII further comprises species that do not relate to a single inventive concept, because they encompass different types of viruses and methods of using such. The viruses encompassed by the groups are:

- I. Paramyxoviridae, drawn to claims 1-21, 50-75, 115, 118-123, 125-134, and 143-156.
- II. Rhabdoviridae,
- III. Orthomyxoviridae,
- IV. Togaviridae,
- V. Flaviviridae,
- VI. Picornaviridae,
- VII. Coroviridae,
- VIII. Reoviridae,
- IX. Poxviridae,
- X. Herpesviridae,
- XI. Parvoviridae,
- XII. Papovaviridae
- XIII. Adenoviridae,
- XIV. Iridoviridae,
- XV. Hepadnaviridae,
- XVI. Alphaviridae, and
- XVII. Varicellaviridae.

The claims are deemed to correspond to the species listed above in the following manner:

Claims that are correspondent to invention groups I, VI, and VII.

The following claim(s) are generic: 1-75, and 86-156.

The inventions listed as Groups II-VII and I do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is a method of infecting a neoplasm with an interferon-sensitive, replication-competent clonal virus in a mammal, whereas the special technical feature of group II is a method of screening tumour cells in a tissue sample using a differential cytotoxicity assay, group II is an in vitro method that do not require in vivo administration of viruses, while the assay of group II is not used in group I.

## INTERNATIONAL SEARCH REPORT

PCT/US00/10204

The special technical feature of group III uses cells competent or deficient in an interferon mediated antiviral activity, whereas groups I and II do not require these cells.

The special technical feature of group IV requires procedures of viral modification; the special technical feature of group V is administering a chemical compound, which will not be required in groups I-IV.

The special technical feature linking groups VII, I, and VI (which do not use in groups II-V) appear to be that they are purified viruses, methods of purifying such, and methods of using the viruses. However, Csatory (US 5,602,023) anticipates group VI, a purified paramyxovirus, and methods of purification by ultracentrifugation, but not group I or VII. Therefore, the technical feature linking the inventions of groups VI, VII and I does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define one contribution as a whole over the prior art. Accordingly, groups I, VI, and VII are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The special technical feature of each of the species of groups I, VI, and VII is drawn to using a species of viruses, each of these viruses has a differing structure, replication strategy, host range, sensitivity to interferon, disease capacity, and genome, therefore, the results from one virus family cannot necessarily be assumed to be the same for all viruses nor would it necessarily be obvious to that if one virus works in the claimed method that all viruses would be as effective. Accordingly, they are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

Applicant is advised that a reply to this Invitation must include an identification of the species that is elected consonant with this requirement, and a list of all claims readable thereon.